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Antibodies (Abs) elicited by influenza viruses often bind with higher affinities to past influenza strains
than to the current strain. This has been associated with the hypothesis of “original antigenic sin” which
postulates that B cell clones elicited by prior exposure are recalled at the expense of generating a strainspecific response to the current strain. It is clear that prior exposures to influenza viruses focus the
response on conserved epitopes of influenza’s hemagglutinin (HA) glycoprotein. Here, pre-exposure to
influenza is shown to affect Ab fine specificity and Ab mediated protection in mice, ferrets, and humans.
Sequential vaccination of mice with antigenically drifted strains of influenza virus elicited a large
proportion of cross-reactive Abs, but also recalled Abs that have a higher affinity for the priming strain
while binding to the same region of HA with different fine specificities. These fine specificities were
modified by somatic hypermutation, which affected the degree of cross-reactivity. Surprisingly, Abs that
bound with relatively low affinities to an antigenically drifted strain effectively neutralized the drifted strain
following passive transfer. This indicates that Abs expressed by recalled B cell clones share some level of
cross-reactivity between antigenically drifted priming and recall strains. This was also observed by
measuring the reactivity of sera to HA of antigenically drifted influenza strains. Similarly, ferrets and
humans sequentially exposed to influenza viruses had Ab repertoires that were focused on epitopes
conserved between recent strains and earlier strains that circulated during their childhood. As influenza
viruses continually mutate, humans had Ab repertoires that were focused on different regions of the HA,
potentially due to unique pre-exposure histories. A recently acquired HA mutation abrogated binding of
Abs predominantly found in middle-aged adults that were unusually susceptible to influenza infection
during the 2013-2014 influenza season. These findings highlight that while weakly cross-reactive Abs can
protect against antigenically drifted strains, shifting the Ab repertoire to partially conserved sites can
focus the response on regions of the virus that undergo continual antigenic drift. Recall of cross-reactive
Abs can thus result in protection or susceptibility to influenza, depending upon the exposure history and
Ab fine specificities.
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ABSTRACT
THE EFFECT OF SEQUENTIAL EXPOSURE TO ANTIGENICALLY DRIFTED STRAINS OF
INFLUENZA ON ANTIBODY SPECIFICITY AND ANTIBODY MEDIATED PROTECTION
Susanne L Linderman
Scott E Hensley
Antibodies (Abs) elicited by influenza viruses often bind with higher affinities to past influenza
strains than to the current strain. This has been associated with the hypothesis of “original
antigenic sin” which postulates that B cell clones elicited by prior exposure are recalled at the
expense of generating a strain-specific response to the current strain. It is clear that prior
exposures to influenza viruses focus the response on conserved epitopes of influenza’s
hemagglutinin (HA) glycoprotein. Here, pre-exposure to influenza is shown to affect Ab fine
specificity and Ab mediated protection in mice, ferrets, and humans. Sequential vaccination of
mice with antigenically drifted strains of influenza virus elicited a large proportion of cross-reactive
Abs, but also recalled Abs that have a higher affinity for the priming strain while binding to the
same region of HA with different fine specificities. These fine specificities were modified by
somatic hypermutation, which affected the degree of cross-reactivity. Surprisingly, Abs that
bound with relatively low affinities to an antigenically drifted strain effectively neutralized the
drifted strain following passive transfer. This indicates that Abs expressed by recalled B cell
clones share some level of cross-reactivity between antigenically drifted priming and recall
strains. This was also observed by measuring the reactivity of sera to HA of antigenically drifted
influenza strains. Similarly, ferrets and humans sequentially exposed to influenza viruses had Ab
repertoires that were focused on epitopes conserved between recent strains and earlier strains
that circulated during their childhood. As influenza viruses continually mutate, humans had Ab
repertoires that were focused on different regions of the HA, potentially due to unique preexposure histories. A recently acquired HA mutation abrogated binding of Abs predominantly
found in middle-aged adults that were unusually susceptible to influenza infection during the
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2013-2014 influenza season. These findings highlight that while weakly cross-reactive Abs can
protect against antigenically drifted strains, shifting the Ab repertoire to partially conserved sites
can focus the response on regions of the virus that undergo continual antigenic drift. Recall of
cross-reactive Abs can thus result in protection or susceptibility to influenza, depending upon the
exposure history and Ab fine specificities.

v

TABLE OF CONTENTS
ACKNOWLEDGMENTS .................................................................................................. III
ABSTRACT ..................................................................................................................... IV
LIST OF TABLES ........................................................................................................... VIII
LIST OF FIGURES .......................................................................................................... IX
LIST OF ABBREVIATIONS ............................................................................................. XI
CHAPTER 1: INTRODUCTION ....................................................................................... 1
A diverse repertoire of B cells express antibodies ................................................................... 2
The germinal center response ..................................................................................................... 4
Memory B cell responses............................................................................................................. 6
Influenza virus ............................................................................................................................... 7
Influenza virus surveillance and vaccine strain selection ........................................................ 9
Original Antigenic Sin ................................................................................................................ 10
Evidence for OAS in other model systems .............................................................................. 11
Development of universal influenza vaccines with sequential exposure strategies. .......... 12
Antigenic properties of influenza hemagglutinin and the description of antigenic sites. ... 13
B cell Immunodominance .......................................................................................................... 16
Experimental Questions ............................................................................................................. 17

CHAPTER 2: ‘ORIGINAL ANTIGENIC SIN’ ANTIBODIES ARE A VALUABLE
COMPONENT OF SECONDARY IMMUNE RESPONSES TO INFLUENZA VIRUSES 19
Summary...................................................................................................................................... 19
Introduction ................................................................................................................................. 19
Results ......................................................................................................................................... 21
Establishment of a mouse model of ‘OAS’.................................................................................... 21
Identification of OAS Abs .............................................................................................................. 22
Specificity and functionality of OAS Abs ....................................................................................... 24
Somatic mutations affect the cross-reactivity of Sb mAbs ............................................................ 26
Discussion ................................................................................................................................... 27
Materials and Methods ............................................................................................................... 30
Figures and Table ....................................................................................................................... 36

CHAPTER 3: POTENTIAL ANTIGENIC EXPLANATION FOR ATYPICAL H1N1
INFECTIONS AMONG MIDDLE-AGED ADULTS DURING THE 2013-2014 INFLUENZA
SEASON ......................................................................................................................... 58
Summary...................................................................................................................................... 58
Introduction ................................................................................................................................. 59
Results ......................................................................................................................................... 59

vi

An HA mutation acquired prior to the 2013-2014 influenza season is antigenically relevant in
middle-aged adults........................................................................................................................ 59
The difference in K166 epitope immunodominance is due to unique pre-exposure history ......... 61
K166 HA-specific Abs are less effective against K166Q HA mutant virus infection ..................... 62
Discussion ................................................................................................................................... 63
Materials and Methods ............................................................................................................... 64
Figures and Tables ..................................................................................................................... 70

CHAPTER 4: CONCLUDING REMARKS AND FUTURE DIRECTIONS ..................... 90
Shifting the antibody response ................................................................................................. 90
Unexpected protection is elicited by low affinity antibodies.................................................. 92
The effect of previous exposure on de novo antibody responses ........................................ 94
Maintaining diversity in the memory B cell repertoire ............................................................ 95
New epitopes are potentially elicited by sequential exposure ............................................... 96
A potential mechanism for OAS ................................................................................................ 98
The effect of previous influenza virus exposure on influenza virus susceptibility .............. 99
Updating the antibody repertoire ............................................................................................ 101
Understanding B cell immunodominance .............................................................................. 101
Concluding Thoughts ............................................................................................................... 104

BIBLIOGRAPHY .......................................................................................................... 108

vii

LIST OF TABLES
Table 1: Identification of a clonally related family of mAbs…………..……………………57
Table 2: HAI titers using sera from healthy donors from the United States…................81
Table 3: HAI titers using sera from healthy donors from Mexico…………………………83
Table 4: Vaccination elicits K166 HA-specific responses…………………………………84
Table 5: Sequential infection in ferrets can elicit K166 HA-specific Abs………………...86
Table 6: Characterization of K166 HA-specific sera……………………………………….88

viii

LIST OF FIGURES
Figure 1. PR8 and S12a are antigenically distinct H1N1 viruses………………………...36
Figure 2. S12a efficiently boosts Abs that react to PR8 HA………………………………38
Figure 3. S12a boosts PR8 Abs at late time points after initial exposure……………….40
Figure 4. PR8-S12a sequential exposure elicits many Abs with a classical OAS
phenotype……………………………………………………………………………………….42
Figure 5. Hybridomas for these experiments were derived from many mice……………43
Figure 6. Most ‘cross-reactive’ mAbs bind better to PR8 compared to S12a…………...44
Figure 7. ‘OAS’ mAbs bind very poorly to S12a……………………………………………45
Figure 8. Fine specificity of mAbs elicited by sequential H1N1 exposure……………….46
Figure 9. The HA Ab response is focused on the Sb antigenic site following sequential
exposure…………………………………………………………………………………………48
Figure 10. Fine mapping of Sb mAbs reveals that most cross-reactive mAbs are not
sensitive to an E156K HA mutation…………………………………………………………..49
Figure 11. Most Sb mAbs elicited by PR8-S12a sequential exposure are not sensitive to
the E156K mutations and protect against PR8 and S12a infection……………………….51
Figure 12. Somatic mutations affect binding to both PR8 and S12a…………………….53
Figure 13. mAbs elicited by PR8-S12a immunization prevent disease caused by PR8
and S12a infections…………………………………………………………………………….55
Figure 14. pH1N1 viruses rapidly acquired HA mutation K166Q during the 2013–2014
influenza season………………………………………………………………………………..70
Figure 15. Sequence variation of pH1N1 HA……………………………………………….72
Figure 16. Adult humans possess Abs that bind to a region of HA that was recently
mutated in pH1N1………………………………………………………………………………74
Figure 17. Mexican donors born before 1985 possess Abs that bind to the region of HA
that was recently mutated in pH1N1………………………………………………………….76
Figure 18. Vaccination of middle-aged adults with the current pH1N1 vaccine strain
elicits Abs that bind to a region of HA that is now mutated in most pH1N1 isolates……77
Figure 19. Ferrets sequentially infected with A/Chile/01/1983 and A/California/ 07/2009
develop K166 HA-specific Abs………………………………………………………………..79
ix

Figure 20. Homology between A/USSR/90/1977, A/Chile/01/1983, and
A/California/07/2009……………………………………………………………………………80
Figure 21. A schematic diagram of the effect of sequential exposure to antigenically
drifted strains of influenza on the specificity and function of the Ab repertoire………...106

x

LIST OF ABBREVIATIONS
Abs
ADCC
BCR
B/Lee
BPL
BrdU
BSA
CCL19
CCL21
CCR7
CD154
CD40
CD45R
CD80
CD86
CDC
CDR
CHOP
CTLs
D
DMEM
DNA
ELISA
FBS
Fc
FDC
FR
GISN
GISRS
HA
HAI
HAU
HEPES
HIV
IMGT
i.p.
i.v.
J
J1
LCMV
mAbs
MBCs
MDCK
MEM

Antibodies
Antibody-dependent cell-mediated cytotoxicity
B cell receptor
B/Lee/1940
Beta-propiolactone
Bromodeoxyuridine
Bovine serum albumin
Chemokine (C-C motif) ligand 19 (ELC, CKb11, MIP-3b, SCYA19)
Chemokine (C-C motif) ligand 21 (ECL, SLC, CKb9, TCA4, SCYA21)
Chemokine (C-C motif) receptor 7 (CD197, EBl1)
CD40L
TNF receptor superfamily member 5
Protein tyrosine phosphatase receptor type C (B220)
B7-1
B7-2
Centers for Disease Control and Prevention
Complementarity determining region
Children’s Hospital of Philadelphia
Cytotoxic T lymphocytes
Diversity
Dulbecco’s modified eagle medium
Deoxyribonucleic acid
Enzyme-linked immunosorbent assay
Fetal bovine serum
Immunoglobulin constant region
Follicular dendritic cell
Framework region
Global Influenza Surveillance Network
Global Influenza Surveillance and Response System
Hemagglutinin
Hemagglutination inhibition assay
Hemagglutination unit
2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid
Human immunodeficiency virus
International immunogenetics information system
Intraperitoneal
Intravenous
Joining
A/Puerto Rico/08/1934-J1
Lymphocytic choriomeningitis virus
Monoclonal antibodies
Memory B cells
Madin-Darby canine kidney
Minimum essential medium
xi

MHC II
NA
NIH
OAS
PBS
PCR
PFU
pH1N1
PNPP
PR8
RIA
RAG
RNA
S12a
SD
SEM
sH1N1
TAE
TCID50
TFH
TLR
TPCK
V
VLRB
WHO
WT

Major histocompatibility complex II
Neuraminidase
National Institutes of Health
Original Antigenic Sin
Phosphate-buffered saline
Polymerase chain reaction
Plaque forming unit
Pandemic H1N1 A/California/07/2009
p-nitrophenyl phosphate
A/Puerto Rico/08/1934
Radioimmunoassay
Recombination-activating genes
Ribonucleic acid
A/Puerto Rico/08/1934-S12a
Standard deviation
Standard error of the mean
Seasonal H1N1
Tris-acetate-EDTA
50% Tissue culture infectious dose
T follicular helper cell
Toll-like receptor
L-(tosylamido-2-phenyl) ethyl chloromethyl ketone
Variable
Variable lymphocyte receptor B
World Health Organization
Wild type

xii

CHAPTER 1: INTRODUCTION

Influenza causes an annual disease burden throughout the world, and has for
centuries. Influenza-like epidemics have been recorded throughout history, though
before the isolation of the causative influenza virus, these epidemics were often
considered to be new diseases, particularly since they frequently overcame previously
acquired immunity (Francis, 1953; Smith et al., 1933). In 1562, Sir Thomas Randolph,
the Ambassador of Queen Elizabeth I to the Court of Mary, Queen of Scots, recorded in
a letter, “May it please your Honour immediately upon the Queen’s arrival here, she fell
acquainted with a new disease that is common in this town, called here the New
Acquaintance, which passed also through her whole Court, neither sparing lord, lady,
nor demoiselle, not so much as either French or English” (Strickland, 1903). Not all
pandemics were equal in their epidemiological distribution though. For instance, English
reports of the pandemic of 1782 describe that children and the elderly were less affected
than middle-aged adults (Francis, 1953).
We now know that influenza viruses frequently cause epidemics because they
can rapidly change, either by acquiring mutations or by gene recombination. In addition,
we know that serum components known as antibodies (Abs) can protect against
infection, and that the Ab repertoire is diverse and can continue to evolve over time
(Briney and Crowe, 2013; Von Stabsarzt and Kutasati, 1890). In chapter two, we will
describe how sequential exposure to variant influenza strains affects the fine specificity
of influenza-specific Abs and influences protection against infection in mice. In chapter
three we will address how pre-exposure history in humans affects the Ab repertoire and
may influence susceptibility to disease. But first in chapter one, we will review
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immunological and virological studies that shape our current knowledge of the B cell
response to influenza and outline the larger immunologic context of the ensuing
experimental questions.
A diverse repertoire of B cells express antibodies
B cells are lymphocytes that have successfully rearranged their immunoglobulin
locus to express functional Abs. Functional Abs consist of four chains: two heavy chains
and two light chains (or up to 6 multiples of that) (Cattaneo and Neuberger, 1987;
Edelman, 1973). Each heavy and light chain of an antibody molecule has a variable
region and a constant region. The variable regions are formed by gene recombination.
In the heavy chain locus, the heavy chain variable region is created by sequential
rearrangements involving one V (variable), one D (diversity), and one J (joining) gene
segment. The light chain variable regions consist of one V gene rearranged to one J
gene (Early et al., 1980; Hozumi and Tonegawa, 1976). In addition to the combinatorial
diversity that is generated by the random rearrangement of these gene segments and by
the independent pairing of the heavy and light chains, additional variability is introduced
at the junctional sequences between the different gene regions as nucleotides can be
added or lost during RAG (recombination-activating gene) mediated recombination (Alt
and Baltimore, 1982). This junctional diversification can include the addition of
palindromic sequences by RAG (P-addition), the addition of random nucleotides by the
enzyme terminal deoxynucleotidyl transferase (N-addition), and the exonucleolytic
nibbling by non-homologous end joining machinery (deletions). Due to the high degree
of junctional diversity, the resulting rearrangement may result in a non-functional
rearrangement (due to shifts in the reading frame or the generation of termination
codons). Should recombination lead to a nonproductive rearrangement, the second
2

immunoglobulin allele can be rearranged. Usually only one allele is expressed (allelic
exclusion), so that B cells usually express only one kind of antibody molecule
(Vettermann and Schlissel, 2010). B cells harboring Abs that exhibit binding to selfantigens in the bone marrow are eliminated or disabled in a process known as negative
selection (Hartley et al., 1991; Vettermann and Schlissel, 2010). In some cases, selfreactive B cells may be saved by modifying the specificity of the antibody through
additional gene rearrangement, a process known as receptor editing (Luning Prak et al.,
2011).
In addition to the variable region genes, each Ab heavy chain also has a constant
region gene that determines the isotype (eg. IgM, IgD, IgG, IgA, or IgE). The isotype
produced by a particular B cell can change over time through class switch recombination
and imparts important functional properties to Ab activity (Stavnezer et al., 2008). For
instance, IgA can be transported to mucosal surfaces such as the gut, and can be
transferred into secretions such as saliva and milk while IgG can be transported across
the placenta and provide early protection to infants (Garty et al., 1994; Palmeira et al.,
2012; Van de Perre, 2003). Ab heavy chain isotypes also differ in their ability to bind to
different Fc receptors which, in turn, can either enhance or suppress the immune
response. This can be further modified by differential glycosylation of the Fc region, thus
altering the type of receptor to which the Fc region can bind (Pincetic et al., 2014). In
addition, changes in isotype have been shown to affect both avidity and affinity to
antigen (Cooper et al., 1993; Tudor et al., 2012). Abs can be secreted as soluble
proteins or expressed on the cell membrane as the B cell receptor (BCR) when
alternatively spliced to include a transmembrane domain.
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The BCR has the ability to bind to particular structural epitopes, and can
transduce a signal across the cell membrane upon binding through its association with
the Igα and Igβ coreceptors (Sanchez et al., 1993). This initial signal leads to significant
changes in the cell that affect antigen uptake, processing, presentation on major
histocompatibility complex II (MHCII), costimulatory molecule expression, and homing
which make B cells effective antigen presenting cells. Naïve B cells circulate through
the blood and lymph and home to secondary lymphoid organs including lymph nodes
and the spleen (Butcher and Picker, 1996). Upon encountering antigen, B cells
upregulate the chemokine receptor CCR7 which binds to the chemokines CCL19 and
CCL21 which are expressed at the interface of the B and T cell zones in secondary
lymphoid organs thus bringing the B cell in closer proximity to T cells (Reif et al., 2002).
In addition, BCR binding also upregulates costimulatory molecules such as CD86 and
CD80 which help the B cell stimulate CD4 helper cells (Lenschow et al., 1994).
Activated B cells also upregulate CD40 which binds to CD154 on activated T cells (Lee
et al., 2003). Not all B cells require T cell help. Some antigens have been shown to
activate B cells in the absence of T cell help, but in conjunction with other activating
signals such as Toll-like receptor (TLR) binding and extensive BCR-crosslinking of
repetitive epitopes (Vos, 2000).
The germinal center response
Activated B cells can follow several different paths. They can become rapidly
dividing plasmablasts that downregulate their surface immunoglobulin and produce
secreted antibodies, they can become plasma cells that secrete even larger quantities of
Ab, or they can become memory B cells (MBCs). Activated B cells can also enter
germinal centers, where they can either die or give rise to MBCs or plasma cells.
4

Germinal centers are located in peripheral lymphoid organs. The established
germinal center is polarized into two zones: the light zone and the dark zone (Röhlich,
1930). The dark zone is commonly associated with increased cell proliferation, somatic
hypermutation, and class switch recombination resulting in a greater diversity of Ab
specificities (Jacob et al., 1991b; Muramatsu et al., 2000; Victora et al., 2010). However,
germinal center B cells can also divide in the light zone which is characterized by the
presence of additional cell types such as follicular dendritic cells (FDC), follicular helper
T cells (TFH), and macrophages (Allen et al., 2007). It is thought that high affinity Abs
are preferentially selected in the light zone by competing for antigen presented on FDCs
and/or competing for help from TFHs and that this results in enhanced proliferation and
survival (Anderson et al., 2009; Gitlin et al., 2014). In addition to competing with other
clones for antigen, individual cells may also need to compete with secreted Ab for
particular epitopes, thus raising the bar for high affinity clones (Zhang et al., 2013).
MBCs emerging from a germinal center response can be long-lived and quiescent until
reactivated (Jacob et al., 1991a; Toyama et al., 2002).
While the mechanism for B cell fate determination is not yet clear, recent studies
have demonstrated that the kinetics of MBCs and long-lived plasma cell development in
the germinal center differ. Using bromodeoxyuridine (BrdU) labeling at different time
points during a germinal center response, it has been determined that the majority of
MBCs arise from divisions occurring during the early germinal center response, whereas
most long-lived plasma cells arise from divisions occurring later on in the response
(Weisel et al., 2016). In addition, destruction of germinal centers at an intermediate time
point of the response by anti-CD154 Ab administration has a greater effect on the longlived plasma cell population than on the MBC population (Weisel et al., 2016). These
5

findings suggest that while the germinal center selects for high affinity clones over time,
it also produces a greater diversity of MBC specificities early on.
Memory B cell responses
MBCs can be long-lived and remain quiescent in the absence of antigen
(Maruyama et al., 2000). However, upon antigen stimulation, MBCs can rapidly become
activated and can differentiate into Ab secreting plasma cells or reenter a germinal
center (Deenick et al., 2013; McHeyzer-Williams et al., 2015). MBCs can be divided into
subsets by several criteria and these subsets of MBCs appear to be poised to follow
different fates upon reactivation. When divided by isotype, IgM+ MBCs are more likely
to reenter germinal centers whereas IgG+ MBCs are more likely to differentiate into Ab
secreting plasma cells (Dogan et al., 2009). MBCs can also be divided into subsets
based on their expression of CD80 and PD-L2 with double positive MBCs (CD80+, PDL2+, predominantly but not exclusively IgG+) more likely to differentiate into Ab secreting
plasma cells, and double negative MBCs (CD80-, PD-L2-, predominantly IgM+) more
likely to form germinal centers (Zuccarino-Catania et al., 2014). Interestingly, the double
negative MBC subset generally also has a lower degree of somatic mutation (Tomayko
et al., 2010), suggesting that MBCs with less somatic mutation are more likely to enter
germinal centers and may be precursors of the higher affinity double positive MBC
subset. While it has been shown that the proportion of these MBC subsets is affected by
precursor frequency, how the mode of exposure or the pathogen itself affects the overall
makeup of the MBC compartment remains to be determined (Tomayko et al., 2010).
This could have implications for the quality and kinetics of MBC responses as well as for
the degree of Ab evolution over time.
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MBCs have advantages over naïve B cells in their sensitivity to reactivation,
proliferation, higher precursor frequency, and reduced requirement for T cell help. There
are many intrinsic differences between naïve and MBCs that may contribute to a larger,
more rapid Ab response during a secondary exposure (Tomayko et al., 2008). Human
MBCs express higher levels of costimulatory molecules such as CD80 and CD86, which
may lead to enhanced stimulation during a secondary response (Liu et al., 1995). MBCs
also initiate proliferation more rapidly and more frequently upon antigenic stimulation
than naïve B cells (Tangye et al., 2003). In addition the increased proportion of classswitched B cell clones in the MBC repertoire may affect the quality of the recall
response; studies comparing B cell clones with identical specificities but different
isotypes demonstrate that the IgG membrane tail increases Ab production and clonal
expansion and reduces cell loss (Martin and Goodnow, 2002). As a primary response
expands clonal populations of antigen-specific B cells, antigen-specific MBCs are also
present at a higher precursor frequency than naïve B cells (Burnet, 1957; Tas et al.,
2016). Finally, while T cell-dependent MBCs specific for soluble monomeric antigens
appear to require T cell help for additional differentiation, virus-specific MBCs have been
shown to differentiate into plasma cells in the absence of T cell help (Hebeis et al., 2004;
Hilbert et al., 1989).
Influenza virus
Influenza viruses are enveloped single-stranded negative sense RNA viruses
with 8 RNA segments (McGeoch et al., 1976). The segmented nature of the viral
genome is important, as reassortment of RNA segments from 2 or more strains can
occur (Marshall et al., 2013). Reassortment can lead to the development of a new
subtype of influenza virus which, when infecting humans, can result in an antigenic shift.
7

The envelope surface proteins include hemagglutinin (HA), neuraminidase (NA), and M2
proteins (Lamb et al., 1985). HA is a homotrimer initially synthesized as the precursor
HA0 but is further cleaved into two subunits, HA1 and HA2, which remain linked by
disulfide bonds (Klenk et al., 1975; Lazarowitz and Choppin, 1975; Skehel and
Waterfield, 1975). Once cleaved, HA aids in viral attachment and entry into a cell. It
binds to sialic acids linked to galactose by predominantly 2-3 or 2-6 linkages. The
frequency of these different types of linkages in different species is thought to contribute
to infectivity of viral strains in different species (Ibricevic et al., 2006; Matrosovich et al.,
2000). Upon viral uptake by endocytosis, a drop in pH in the endosome induces a
structural change in the HA which allows the viral membrane to fuse with the endosomal
membrane, allowing the contents of the virion to be released into the cytosol (Gray and
Tamm, 1998). NA aids in viral release by cleaving sialic acid linkages thus preventing
the HA of newly formed virions from remaining bound to the infected cell (Palese et al.,
1974). M2 is a proton-selective ion channel that is thought to control the pH of the virion
in the endosome before membrane fusion, and also in the golgi apparatus to maintain
HA conformational stability (Takeda et al., 2002; Takeuchi and Lamb, 1994). It also
binds to the M1 protein, affecting virion structure, and is required for influenza virus
induced inflammasome activation (Ichinohe et al., 2010; McCown and Pekosz, 2006).
Most influenza virus neutralizing Abs bind the HA protein and neutralize either by
blocking attachment, preventing fusion, or mediating other Ab mediated mechanisms of
protection such as antibody-dependent cell-mediated cytotoxicity (ADCC) (DiLillo et al.,
2014; Ekiert et al., 2009; Knossow et al., 2002). However, due to the influenza virus’s
error-prone polymerase, and the mutational permissiveness of HA, mutations can rapidly
become fixed in the circulating viral population. This gradual accumulation of mutations
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over time is known as antigenic drift. The membrane distal HA head domain (in contrast
to the more membrane proximal stalk or stem domain) is particularly permissive of
mutation and these mutations can significantly affect the binding of previously elicited
Abs (Heaton et al., 2013). Because of this loss in Ab specificity, a previously protected
individual can become susceptible to newly drifted strains of influenza virus. In addition,
HA mutations not only affect the antigenic properties of the HA, but also its affinity for
sialic acid (Hensley et al., 2009).
Influenza virus surveillance and vaccine strain selection
As influenza viruses are constantly acquiring mutations, new mutant strains that
abrogate Ab binding in at least a subset of the human population can arise and supplant
circulating strains that are more easily neutralized by preexisting immunity. To monitor
these constant changes, the World Health Organization (WHO) has developed a
surveillance system known as the Global Influenza Surveillance and Response System
(GISRS) (formerly known as the Global Influenza Surveillance Network or GISN). In this
system, thousands of viral isolates collected from influenza virus infected individuals are
screened for their genetic and antigenic properties. To determine whether a virus is
antigenically distinct compared to previously circulating strains, the clinical isolates are
tested by hemagglutination inhibition assay (HAI). The HAI assay tests the ability of
antisera to inhibit influenza virus’s ability to hemagglutinate red blood cells. The antisera
used in these screens are primarily collected from ferrets that were infected with the
previously circulating strain, or in more limited cases antisera collected from humans are
used. The WHO makes recommendations on which strains should be included in the
next vaccine based on whether or not the antisera elicited by the previous year’s vaccine
are still able to inhibit hemagglutination mediated by the new isolate. The WHO also
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considers results from microneutralization assays completed with a subset of clinical
viral isolates. These assays measure neutralizing Abs against both the HA head and
stalk (Network, 2011).
Original Antigenic Sin
Studies of influenza virus-specific Abs in human sera demonstrate that the Ab
repertoire differs among different age groups and that the specificity of human sera is
skewed toward those strains that would have circulated when an individual was a child
(Davenport and Hennessy, 1956; Davenport et al., 1953; de St.Groth and Webster,
1966a; Francis, 1955). This has been recapitulated in multiple animal models (de
St.Groth and Webster, 1966b; Kim et al., 2009; Virelizier et al., 1974; Webster, 1966).
As structural analogues can recall previously elicited B cell clones (Deutsch et al., 1973;
Eisen, 1969), it has been hypothesized that B cell clones specific for the initial strain are
recalled by antigenically related strains experienced later in life (de St.Groth and
Webster, 1966a; Li et al., 2013; Wrammert et al., 2011). However, Abs expressed by B
cell clones recalled by a structural analogue frequently bind with a higher affinity to the
priming antigen (Eisen, 1969). Though these B cell clones are often cross-reactive (de
St.Groth and Webster, 1966b; Eisen, 1969; Fish et al., 1989; Webster et al., 1976), this
observation was termed original antigenic sin (OAS) as the Abs expressed by the
recalled clones have a higher affinity for past strains while the magnitude of strainspecific Ab titers specific for the more recent strain is frequently reduced (Francis, 1955).
This reduction in strain-specific Ab titers to the more recent strain can be limited in a
number of ways. For instance, while sequential infection with live virus leads to a
reduction in strain-specific Ab titers that are specific exclusively for the more recent
strain, sequential vaccination with inactivated virus does not result in an Ab titer
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reduction (de St.Groth and Webster, 1966b; Kim et al., 2009). Whether this is due to a
difference in dose, or due to a difference in the site of exposure is not yet understood. It
is clear however, that the viral titers after a secondary infection are often lower in
animals pre-exposed to antigenically drifted strains, suggesting that cross-reactive
protection that reduces viral titers to the newer strain most likely contributes to a
reduction in a novel Ab response (Kim et al., 2009). Many aspects of OAS might
therefore simply result from decreased antigen loads during secondary exposures.
Evidence for OAS in other model systems
OAS has also been described in other systems using structurally related
antigens. The haptens arsanilic acid and sulfanilic acid are two such structural
analogues. While immunization with arsanilic acid elicits the dominant expression of
Abs encoded by a particular heavy chain variable region, immunization with sulfanilic
acid does not elicit the expansion of these B cell clones unless mice have been primed
with arsanilic acid. Additionally, these Abs bind with a higher relative affinity to arsanilic
acid than to sulfanilic acid (Fish et al., 1989). OAS has also been described after
sequential exposure to serologically distinct variant bacterial strains (termed serovars).
Studies describing sequential exposure to different serovars of Chlamydia trachomatis
demonstrate a boost in Ab titers to the priming serovar, an increase in cross-reactive
serum titers, and an altered Ab repertoire after heterologous exposure (Berry et al.,
1999). OAS has also been demonstrated after sequential exposure to different subtypes
of dengue virus and is also hypothesized to play a role in the evolution of the antibody
response to HIV (Ciupe et al., 2011; Halstead et al., 1983).
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An OAS-like phenomenon has also been described for cytotoxic T lymphocytes
(CTLs) in response to sequential infection with variant strains of lymphocytic
choriomeningitis virus (LCMV), dengue virus, and HIV (Klenerman and Zinkernagel,
1998; Mongkolsapaya et al., 2003; Ueno et al., 2007). In the cases of LCMV and
dengue virus, activated CTLs are found to be directed against the priming strain rather
than a new variant. In the case of HIV, the variant-specific CTL population expands but
has reduced cytotoxic activity compared to CTLs specific for the priming strain.
Development of universal influenza vaccines with sequential exposure strategies.
According to the doctrine of OAS, the Ab repertoire is skewed towards clones
that have been previously elicited by earlier circulating strains. This has been thought to
result in both positive and negative effects. On the one hand, it can skew the Ab
repertoire to more conserved sites. Should these conserved sites be broadly conserved
and maintained, due to structural or functional constraints, Abs specific for these sites
have the potential to be more broadly cross-reactive and may provide protection against
a broader repertoire of viral strains. On the other hand, should the Ab response be
shifted to epitopes that are not neutralizing or that are not broadly conserved, this could
reduce protection against other strains. In addition, the reduction in Ab titers specific for
newly formed epitopes can reduce protection against newly drifted strains. Shifting Ab
immunodominance to highly conserved sites is the target of several experimental
vaccine regimens designed to broaden and increase protection against rapidly mutating
and diverse viral populations (Krammer et al., 2013; Malherbe et al., 2011; Wang et al.,
2010; Wei et al., 2010). While sequential vaccination has been successfully used to
increase the proportion of Abs elicited to conserved regions of the HA, this has been a
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transient effect that is lost upon re-exposure to an antigenically related strain (Andrews
et al., 2015; Ellebedy et al., 2014).
Antigenic properties of influenza hemagglutinin and the description of antigenic
sites.
The earliest documented way of experimentally determining if two influenza virus
strains were antigenically similar was to test if one strain elicited a protective response
against another, either by challenging pre-infected ferrets with a second strain, or by
incubating a viral strain with antisera collected from previously infected ferrets or
humans and then testing its infectivity (Smith et al., 1933).
With the discovery of the hemagglutination property of influenza viruses, the HAI
assay became a widespread method for testing the degree of antigenic difference (Hirst,
1941). Unfortunately, as the HAI assay only measures the ability of serum to inhibit
influenza virus’s ability to hemagglutinate red blood cells, it only measures the subset of
the Ab repertoire that inhibits hemagglutination. For example, stalk-specific Abs as well
as select Abs specific for the HA head domain fail to inhibit virus mediated
hemagglutination, and are therefore not measured by the HAI assay. However, this was
not apparent during early studies of the influenza antibody response, as the binding
footprints of HA-specific Abs and their effect on hemagglutination as well as
neutralization were unknown.
Several approaches were taken to determine the regions of the HA where
antibodies bind, otherwise known as the antigenic sites of HA. The structure of the H3
HA from A/Hong Kong/1968 was solved in 1980 (Wilson et al., 1981). Using sequences
of previously circulating H3N2 viruses as well as laboratory variants that had been
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isolated after incubation with monoclonal antibody (mAb) or most-avid-fraction Ab, amino
acids that differed between isolates were mapped to the HA structure (Wiley et al.,
1981). The combination of the sequence and structural data led to the description of 4
different antigenic regions of the A/Hong Kong/1968 H3 HA (A, B, C, and D). Not all
mutations were considered to be antigenically relevant with some characterized as
antigenically neutral based on their location on the HA structure. A mutation may be
antigenically neutral as any mutation may be positively selected for enhanced viral
fitness or structural stability independent of Ab binding, or may accumulate due to the
stochastic nature of viral mutation. In addition, some mutations, particularly those
located at the interface of the HA subunits, may indirectly affect Ab binding by altering
more distant epitopes, and may therefore not be in an antibody footprint themselves.
However, this does not preclude the possibility that apparently neutral mutations may be
antigenically relevant in a different context, such as in individuals with different antibody
repertoires or due to the loss of a glycosylation site (Skehel et al., 1984). As this process
of delineating antigenic sites depends on mapping HA mutations, it may also overlook
residues in potential antibody footprints that are functionally constrained and therefore
not mutated in infectious virus, or non-neutralizing Abs that do not positively select for
HA mutations.
The H1 HA antigenic sites were initially mapped differently. Rather than mapping
mutations directly to the HA structure and dividing these into different regions based on
structural components, viral mutants isolated after incubation with neutralizing mAb were
grouped based on the binding characteristics of a panel of virus-specific mAbs
developed after primary or secondary exposure to A/Puerto Rico/08/1934 (PR8) in
BALB/c mice (Gerhard et al., 1981). Viral mutants that abrogated binding of a particular
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set of mAbs were grouped separately from viral mutants that bound to those mAbs but
failed to bind to others. Four antigenic sites were initially assigned based on antibody
binding rather than topology. These were known as the Sa, Sb, Ca, and Cb sites.
These are not necessarily discrete sites, as some mAbs overlapped multiple antigenic
sites (Gerhard et al., 1981; Lubeck and Gerhard, 1981). Once the viral mutants in each
antigenic site were sequenced and mapped to the H3 HA structure, the antigenic sites
were found to group together in different topographically distinct regions of the HA head
group with the Sa and Sb sites located on the distal end of the head and the Ca (further
subdivided into the Ca1 and Ca2 subgroups) and Cb sites located more proximally to the
membrane (Caton et al., 1982).
Recent advances in sequencing technology have aided the continued description
of HA antigenic sites. Antigenicity of particular residues as described by potential codon
bias towards diversification, positive selection of amino acids, and entropy and likelihood
ratios in large cohorts of HA sequences have correlated with the previously described
antigenic sites, but new potential antigenic residues have also been identified (Bush et
al., 1999; Huang et al., 2012; Plotkin and Dushoff, 2003). In addition, co-crystallizations
of mAb bound to HA has elucidated new binding sites, particularly in highly conserved
regions where mutations are rare or impossible due to functional constraints (Dreyfus et
al., 2013). This is of particular importance to the understanding of antigenic sites as Abs
that bind to highly conserved, rarely mutated sites are potentially broadly neutralizing
and may protect against a wider diversity of strains despite antigenic drift. The original
naming schemes of the antigenic sites described for the A/Hong Kong/1968 and PR8 HA
are often appropriated for other viral strains, and new naming schemes for particular
strains have been proposed (Huang et al., 2012). However, caution should be exercised
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when applying these defined antigenic sites to new strains as the HA structure has
evolved over time, and our understanding of HA antigenicity continues to advance.
B cell Immunodominance
While most PR8-specific mAbs can be mapped to the dominant antigenic sites
previously mapped on the HA head domain, the site dominance differs between the
early primary and secondary responses. For instance, approximately 50% of the early
primary mAbs in BALB/c mice are specific for the Cb site and many of these mAbs share
a limited set of light and heavy chain regions (Kavaler et al., 1990). However, these
clones (that can be recognized by an Ab specific for a light chain-associated idiotope
known as 23-1 Id) are not recalled by a secondary exposure (Kavaler et al., 1991). Why
this particular set of epitopes is immunodominant in the primary response and not after a
secondary response is not known. More recent studies on this particular specificity
suggest that the early PR8 Cb response relies predominantly on extrafollicular
responses, although low numbers of 23-1 Id+ cells with germinal center markers
(CD45Rhi CD38lo CD24hi) are also evident (Rothaeusler and Baumgarth, 2010).
Why epitopes of the HA head are more immunodominant than more conserved
epitopes located in the stalk region of the HA is unknown. Some have hypothesized that
the subdominance of stalk epitopes may be due to steric hindrance as viral glycoproteins
are clustered together tightly at the viral surface. This steric hindrance is maintained
when HA is solubilized by bromelain mediated cleavage from the membrane as the HA
molecules aggregate and form rosettes (Kawasaki et al., 1983). Interestingly, recent
research in lampreys has shown that even the structurally unrelated variable lymphocyte
receptor B (VLRB) response is targeted towards the HA head when these jawless
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vertebrates are immunized with inactivated influenza virus (Altman et al., 2015). The
immunodominance of the HA head region is therefore not immunoglobulin or species
specific, but may rather be due to some inherent chemical or structural components.
Multiple strategies to overcome subdominance have been proposed, from sequential
vaccination as described above, to expanding the B cell repertoire by adding adjuvants
to the immunogen (Clegg et al., 2012; Goff et al., 2013; Khurana et al., 2011a).
Experimental Questions
The theory of OAS is somewhat paradoxical to the theory of B cell clonal
selection as it posits that antigenically drifted strains of influenza recall B cell clones
specific for an earlier circulating strain that are not well adapted for the present strain.
While this has been documented in both humans and various animal models, the fine
specificity of OAS Abs that have a higher affinity for the priming antigen than the recall
antigen, and their potential role in protection against the current strain have not been
carefully described. We address this question in chapter two by sequentially immunizing
mice with antigenically drifted strains of influenza. We analyze mouse sera, and
generate hybridomas from sequentially immunized mice. We map the fine specificities
of the mAbs derived from these hybridomas by testing their binding by ELISA to a large
panel of mutant viruses to determine how pre-exposure history affects the specificity of
the Ab repertoire. To determine the role of OAS Abs in protection against the
contemporary influenza strain, we test the ability of mAbs to neutralize influenza virus
infection in vivo by passive transfer experiments in mice. Our data suggest that the
threshold of cross-reactivity required to recall B cell clones that are specific for previous
strains is low, but that it has an effect on the fine specificity on the Abs that are recalled
and that these OAS Abs contribute to protection against an antigenically drifted strain.
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This is important, as it changes our understanding of OAS and how the Ab repertoire is
affected by sequential exposure to influenza viruses.
In chapter three, we complete a series of experiments to determine how previous
influenza exposures shape human Ab responses against new viral strains. It has been
shown that individuals from different age groups can have Ab repertoires that are
focused on different antigenic sites and this is hypothesized to be due to different
influenza virus pre-exposure history (Davenport et al., 1953). We hypothesize that this
might contribute to age group specific susceptibility to influenza strains that have
acquired mutations that abrogate binding of Abs prevalent in a particular age group. In
the 2013-2014 influenza season, middle-aged adults were affected by an unusually high
influenza disease burden. We hypothesize that this is due to the recent acquisition of a
mutation that abrogates binding to Abs prevalent in middle-aged adult sera. To test this
theory, we analyze human sera from healthy human blood donors, humans vaccinated
with the A/California/07/2009 strain (pH1N1), and ferrets sequentially infected with
circulating H1N1 strains. These experiments not only address questions regarding
current influenza surveillance methodology, but also contribute to our understanding of
how influenza repertoire differences in humans affect protection to antigenically drifted
circulating strains of influenza.
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CHAPTER 2: ‘ORIGINAL ANTIGENIC SIN’ ANTIBODIES ARE A
VALUABLE COMPONENT OF SECONDARY IMMUNE
RESPONSES TO INFLUENZA VIRUSES
Summary
Human Abs elicited by influenza viruses often bind with a high affinity to past
influenza virus strains, but paradoxically, bind poorly to the viral strain actually eliciting
the response. These Abs have been referred to as ‘original antigenic sin’ Abs. Using a
mouse model, we find that OAS and non-OAS Abs target the same general region of the
influenza HA and that somatic hypermutation can modify the degree of cross-reactivity of
OAS Abs. Surprisingly, although OAS Abs bound with very low affinities, some were
able to effectively neutralize an antigenically drifted viral strain following passive transfer
in vivo. Taken together, our data indicate that OAS Abs share some level of crossreactivity between priming and recall viral strains and that these Abs can be protective
when recalled into secondary immune responses.
Introduction
Influenza viruses continuously acquire mutations in antigenically important
regions of the HA and NA proteins through a process termed ‘antigenic drift’. Single HA
mutations can dramatically reduce Ab recognition of influenza viruses (Caton et al.,
1982). Although influenza infections lead to strain-specific lifelong immunity (Yu et al.,
2008), humans are routinely re-infected with antigenically drifted influenza strains
throughout life. Most humans are infected with seasonal influenza viruses by 3 years of
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age (Bodewes et al., 2011) and then re-infected with antigenically drifted strains every 510 years (Kucharski et al., 2015).
Influenza infections early in life can leave long-lived immunological imprints. In
1960, Thomas Francis coined the term ‘original antigenic sin’ to describe the observation
that Abs primed by older viral strains often dominate secondary responses elicited by
new antigenically drifted viral strains (Francis, 1960). The ‘S’ in OAS refers to the
observation that the recall of Abs generated against past strains can occur at the
apparent expense of generating de novo Abs that react to new viral strains (de St.Groth
and Webster, 1966a; Francis, 1960). It is thought that OAS Abs are detrimental to the
host since they react poorly to the viral strain that is actually recalling them.
While it is clear that the majority of human influenza infections take place in the
context of a previously exposed host, most animal models do not take prior-exposures
into account. Recently, Jacobs and colleagues established a mouse model of OAS (Kim
et al., 2012; Kim et al., 2009). These studies show that OAS Abs can be elicited in mice
following sequential exposures with antigenically distinct influenza strains. Here, we
used a similar mouse model to determine the precise binding footprints and
neutralization efficiencies of OAS Abs elicited by sequential influenza exposures.
Surprisingly, we found that many OAS Abs target the same general region of HA that is
recognized by non-OAS Abs. Further, we found that OAS Abs can be highly effective at
neutralizing antigenically distinct viruses in vivo and that B cells producing OAS Abs are
clonally related to B cells that produce non-OAS Abs. Taken together, our data suggest
that OAS Abs are a valuable protective component of secondary influenza immune
responses.
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Results
Establishment of a mouse model of ‘OAS’
We established a mouse model to determine how prior H1N1 influenza A virus
exposures influence the generation of new Ab responses against antigenically drifted
H1N1 strains. For these studies, we utilized the well-characterized A/Puerto
Rico/8/1934 (PR8) and A/Puerto Rico/8/1934-S12a (S12a) H1N1 strains (Caton et al.,
1982; Das et al., 2013; Gerhard et al., 1981). Early mAb mapping studies demonstrated
that there are 4 dominant antigenic sites on the globular head region of the HA of PR8
(Gerhard et al., 1981). The HAs of PR8 and S12a differ by 13 mutations spread across
the 4 dominant HA head antigenic sites (Figure 1A) (Caton et al., 1982; Das et al.,
2013). PR8 and S12a viruses are antigenically distinct as determined by HAI assays
(Figure 1B-C), which measure Ab inhibition of virus binding to red blood cells. Although
the HA stalk region of these viruses is identical (Figure 1A), 98% of PR8-elicited mAbs
fail to recognize a virus closely related to the S12a virus in direct binding assays (Das et
al., 2013).
We exposed mice to the PR8 virus and then re-exposed the same mice 28 days
later with the identical PR8 virus or the antigenically distinct S12a virus. Initial viral
exposures were given via the intraperitoneal (i.p.) route and secondary exposures were
given via the intravenous (i.v.) route. Secondary exposures were delivered via the i.v.
route to enhance our ability to derive hybridomas from sequentially exposed mice.
We first measured PR8-reactive Abs in sera collected from these mice. As
expected, PR8-reactive Abs were boosted upon re-exposure with PR8 (Figure 2A).
Surprisingly, the antigenically distinct S12a virus was also able to boost PR8-reactive
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Abs to levels comparable to those elicited by a homologous PR8-PR8 prime-boost
(Figure 2A). This boosting of the PR8 response was not due to non-specific activation of
B cell clones initiated by the first viral exposure, since an influenza B strain (B/Lee/1940;
unrelated to the PR8 and S12a H1N1 influenza A strains) did not boost PR8 Abs in mice
originally exposed to PR8 (Figure 2A). Similar results were obtained when we exposed
mice with S12a virus 70 days after the initial PR8 exposure (Figure 3A). Since HAI
assays only detect Abs directed against the globular head of HA, we completed
additional direct ELISA binding assays. Consistent with our HAI data, PR8-reactive Abs
detected by ELISA (which measure head and stalk HA Abs) were similar in sera
collected from mice sequentially exposed to PR8 twice and mice sequentially exposed to
PR8 and the antigenically distinct S12a virus (Figure 3B).
Classically, OAS describes the process by which B cells stimulated by past viral
exposures dominate and suppress the generation of de novo activated B cells that
recognize new antigens present in drifted viral strains (Francis, 1960). To determine if
PR8 pre-exposure prevents the generation of de novo Ab responses capable of
recognizing S12a, we measured levels of S12a-reactive Abs in sequentially exposed
mice. Similar levels of S12a-reactive Abs were present in S12a exposed mice with or
without prior PR8 exposure (Figure 2B). Taken together, our data suggest that in PR8exposed mice, S12a elicits Abs that react to the antigenically distinct PR8 strain but that
this does not occur at the expense of eliciting S12a-reactive Abs.
Identification of OAS Abs
Our experiments using sera cannot distinguish whether cross-reactive Abs are
preferentially elicited in sequentially exposed mice or if PR8-specific Abs and S12a22

specific Abs are both elicited in sequentially exposed mice. To determine the specificity
of Abs elicited in our experimental system, we created a panel of 289 hybridoma cell
lines from mice exposed to only PR8, to only S12a, sequentially to PR8 twice, or
sequentially to PR8 and S12a (Figure 4). Hybridoma cell lines were created from a total
of 23 mice (Figure 5). Consistent with previous studies (Das et al., 2013), a single PR8
exposure elicited mAbs that bound with a high affinity to PR8 but not S12a (Figure 4A).
Likewise, the majority of mAbs elicited by a single S12a exposure bound with a high
affinity to S12a but not to PR8 (Figure 4B). Most mAbs elicited by PR8-PR8 sequential
exposure bound with a high affinity to PR8 and not S12a, although some mAbs elicited
under these conditions were able to bind to both viruses (Figure 4C). Sequential
exposure with PR8 and S12a elicited a higher proportion of mAbs that were able to bind
with a high affinity to both PR8 and S12a (Figure 4D; p < 0.05; Fisher’s exact test).
Almost all of these cross-reactive mAbs bound to PR8 better than to S12a (sample
binding curves shown in Figure 6). S12a-specific mAbs were also elicited by PR8-S12a
sequential exposure (Figure 4D). Strikingly, approximately half of the mAbs elicited by
sequential exposure to PR8 and S12a bound with a high affinity to PR8 and not S12a
(Figure 4D). Most of these ‘OAS’ mAbs bound to S12a so poorly that actual binding
affinities to S12a could not be calculated using standard ELISA assays (Figure 7). As a
control, we attempted to create hybridoma cell lines from PR8-exposed mice that were
subsequently exposed to an unrelated influenza B strain. We were unable to isolate
PR8-reactive mAbs under these conditions, which indicates that some level of antigenicrelatedness is required to recall PR8-reactive Abs in PR8 pre-exposed mice.
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Specificity and functionality of OAS Abs
We mapped the binding footprints of each mAb by measuring binding to a large
panel of PR8 viruses that possessed single mutations in the HA (Figure 8). Our mutant
PR8 viral panel included previously characterized mAb escape mutants (Caton et al.,
1982), as well as new escape mutants that we isolated after incubating PR8 virus with
mAbs from this study (for example, the K189N HA mutant was isolated after growing
PR8 virus in the presence of the H5-60A mAb). We tested mAb binding to viruses that
possessed single mutations across the 4 dominant HA antigenic sites (Sa, Sb, Ca, and
Cb). The majority of mAbs isolated from mice sequentially exposed to PR8-PR8 and
PR8-S12a did not bind to PR8 viruses possessing Sb mutations (Figure 8A-B, Figure 9),
indicating that both PR8-PR8 and PR8-S12a sequential exposures elicit an Ab response
that is immunodominant against epitopes in the Sb antigenic site of HA. Approximately
½ of the Sb mAbs isolated from mice sequentially exposed to PR8 and S12a displayed a
classical OAS phenotype since they bound poorly to S12a (Figure 8B). Importantly, the
other ~ ½ of the Sb mAbs isolated from mice sequentially exposed to PR8 and S12a
were cross-reactive with strong binding to both PR8 and S12a (Figure 8B). mAbs
isolated from mice receiving only a single PR8 or S12a exposure reacted to all 4 HA
globular head antigenic sites and were not as frequently directed against the Sb
antigenic site (Figure 9), indicating that sequential viral exposure focused the Ab
response towards the Sb antigenic site.
We next sought to determine if there are fine specificity differences that
distinguish Sb mAbs isolated from mice exposed with PR8-PR8 compared to PR8-S12a.
To do this, we completed additional mAb binding experiments with a larger panel of PR8
viruses with single Sb mutations (Figure 10). There was a notable key difference in the
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binding footprint of Sb mAbs isolated from mice sequentially exposed to PR8-PR8
compared to PR8-S12a: the majority (70%) of Sb mAbs isolated from mice sequentially
exposed twice with PR8 failed to bind to viruses with a mutation at HA residue 156,
whereas the minority (20%) of Sb mAbs isolated from mice sequentially exposed with
PR8 and S12a were sensitive to the 156 mutation (Figure 11A-B and Figure 10). This is
important because the Sb antigenic site of PR8 and S12a differ at residue 156 (PR8 has
E156 and S12a has K156). Most of the ‘OAS’ Sb Abs that were elicited by PR8-S12a
sequential exposure did not bind to PR8 viruses with an E156K HA mutation (these Abs
had a similar footprint to most Sb Abs elicited by PR8-PR8 sequential exposure),
whereas most of the cross-reactive Sb Abs elicited by PR8-S12a sequential exposure
were less affected by the E156K mutation (Figure 8B and Figure 10).
To determine if mAbs isolates from mice sequentially exposed to PR8 and S12a
can protect against viral infection, we completed a series of passive transfer studies in
mice. We transferred mAbs that were either sensitive (H2-S37B) or resistant (H4-S10B)
to the E156K HA mutation and we then challenged mice with either PR8 or S12a virus.
Both mAbs protected mice against PR8 infection (Figure 11C). The H2-S37B mAb that
was sensitive to the PR8 E156K HA mutation failed to protect mice against the S12a
virus, however the H4-S10B mAb that was resistant to the PR8 E156K HA mutation fully
protected mice against the S12a virus (Figure 11D). The E156K-resistant mAb was able
to protect against S12a virus infection, despite binding to S12a with a much lower affinity
compared to PR8 (Figure 8B).
These data suggest that sequential exposure with PR8 and S12a elicit two
closely related but clearly distinct types of Sb-specific Abs. The first type of Ab displays
a classical OAS phenotype in that these Abs have minimal cross-reactivity to S12a or a
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PR8 virus engineered to have the E156K HA mutation, which is the mutation that is
largely responsible for the Sb antigenic difference between PR8 and S12a. The second
type of Ab targets the same general Sb region but binds strongly to both PR8 and S12a
and is not sensitive to variation at residue 156. These cross-reactive Abs appear to
have a narrower binding footprint based on our binding assays using a large panel of Sb
mutant PR8 viruses (Figure 10).
Somatic mutations affect the cross-reactivity of Sb mAbs
In an attempt to identify clonally related mAbs, we sequenced the heavy and light
chains of a number of our hybridoma cell lines. We identified a group of 6 clonally
related IgG2a mAbs derived from a single mouse that was sequentially exposed to PR8
and S12a (Table 1). These 6 related mAbs had different binding affinities to PR8 and
S12a (Figure 12). For example, the H5-42B mAb had very weak binding to S12a (Figure
12A), whereas the H5-61B mAb, which differed by only 4 amino acids in the heavy chain
relative to H5-42B (1 CDR1, 2 FR3, and 1 CDR3 differences), had dramatically
increased binding to S12a (Figure 12B). The H5-61B mAb bound better to a PR8
mutant virus possessing the E156K Sb mutation compared to the H5-42B mAb (Figure
8). It is unclear if the mutations that differentiate H5-42B and H5-61B originated during
the initial priming with the PR8 virus or during the secondary recall response against
S12a. Regardless, these data suggest that somatic mutations can influence the level of
cross-reactivity of Abs elicited by secondary influenza exposures.
To determine if the H5-42B and H5-61B mAbs have different protective
efficiencies, we completed in vivo passive transfer experiments. As an added control,
we measured HAI titers of sera collected 12 hours after mAb transfer at the time of
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infection. Ab titers were not significantly different between mice receiving the H5-42B or
H5-61B mAbs, and the average HAI titer against PR8 was 50, which is well below the
average HAI titers of 140 elicited after a primary response to immunization with 1000
HAU PR8 (Figure 13C). Both the H5-42B and H5-61B mAbs inhibited PR8 infection
following passive transfer in vivo (Figure 13A). Surprisingly, despite the observation that
H5-42B binds poorly to S12a (Figure 8), both mAbs also inhibited S12a infection
following passive transfer in vivo (Figure 13B). The H5-61B mAb, which had a higher
relative binding affinity to S12a compared to H5-42B, was more protective following
S12a infection in vivo compared to H5-42B (Figure 13B). As a comparison, we also
tested mAbs isolated from mice following a primary PR8 exposure (the H0-P2D5D10
mAb) or a primary S12a exposure (the H7-S2-2A mAb). As expected, the PR8 primary
mAb protected mice only against PR8 infection and the S12a primary mAb protected
mice only against S12a infection (Figure 13A-B). Importantly, the S12a primary mAb
protected mice against S12a infection to the same extent as the H5-42B mAb elicited by
PR8-S12a sequential exposure. These data indicate that Abs elicited by sequential
exposures can be highly effective at neutralizing the virus that recalls them, even though
they often bind with a much higher affinity to the first viral strain that the host
encountered. These Abs can be as effective as Abs elicited in a previously naïve host.
Discussion
Most vaccines elicit protective Abs and MBCs that are poised to respond quickly
to a secondary exposure (Plotkin, 2010). Formulating effective vaccines against rapidly
changing pathogens, such as influenza viruses, is challenging (Hensley, 2014; SchultzCherry and Jones, 2010; Stohr et al., 2012). Influenza vaccines are less effective when
viruses acquire mutations in Ab binding sites on the HA, as was the case during the
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2014-2015 influenza season (Chambers et al., 2015). B cells primed against older
influenza strains are recruited upon exposure with new influenza strains, even when
major HA antigenic changes have occurred. For example, prior seasonal H1N1 (sH1N1)
exposure heavily influenced the types of Abs that were elicited in humans against the
2009 pandemic H1N1 strain (Li et al., 2012; Li et al., 2013; Linderman et al., 2014;
Wrammert et al., 2011). mAbs isolated from humans exposed to the 2009 pH1N1
recognize epitopes that are conserved on older sH1N1 strains, and these mAbs have a
high level of somatic mutation indicating that they were likely derived from a memory B
cell pool (Wrammert et al., 2011). Immune skewing towards epitopes present in older
viral strains is likely a result of MBC clones outcompeting naïve B cell clones that are
specific for epitopes present in new viral strains (Engels et al., 2009; Kometani et al.,
2013; Liu et al., 2012). In the case of the 2009 pH1N1 strain, many of these crossreactive mAbs were protective and so the recall of B cell clones originally primed by
sH1N1 viruses was likely advantageous to the host.
There is evidence that prior influenza exposures can negatively affect priming of
Ab responses against new viral strains through a process commonly called OAS
(Davenport et al., 1953; Fazekas de St and Webster, 1966; Francis, 1955; Francis,
1960; Webster, 1966). Prior influenza exposures can decrease the generation of de
novo Ab responses, but this is partially due to cross-reactive immunity (originally elicited
by prior exposures) eliminating antigen following secondary exposure with antigenically
drifted strains (Kim et al., 2009). New Ab responses are not primed effectively when
cross-reactive Abs limit antigen levels. In this context, prior immunity is again
advantageous because Abs elicited against prior influenza exposures are partially
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protective and limit the amount of virus and antigen expressed upon secondary
exposure.
A poorly understood component of OAS is that antigenically distinct viruses recall
some Abs that paradoxically only react to older viral strains and not to the viral strain that
is actually eliciting the response. Our data indicate that there are surprisingly only subtle
differences between OAS and cross-reactive Abs. We expected that sequential
exposure with the PR8 and S12a strains would elicit Ab responses directed towards the
HA stalk, since this region of HA is fully conserved between the two viral strains.
However, we found that the majority of Abs elicited by PR8-S12a sequential exposure
were directed against the Sb antigenic site of HA, which differs significantly between the
two viral strains. Some Sb-specific mAbs elicited by sequential exposure exhibited a
classical OAS phenotype in that they bound very poorly to S12a but bound with a high
affinity to PR8. Other Sb-specific mAbs elicited in the same mice were more crossreactive and bound to both PR8 and S12a. The most important part of our study is that
we discovered that both OAS and cross-reactive Sb Abs recognized the same epitope
within the Sb antigenic site and that cross-reactive Sb Abs were more tolerant of
antigenic differences within this epitope. Very few somatic mutations were required to
increase S12a-reactivity of OAS Abs, indicating that OAS and cross-reactive Abs can be
clonally related.
Although OAS Abs are typically thought of as detrimental, OAS Abs elicited in
our experiments were able to protect mice from S12a infections in passive mAb transfer
experiments. This, along with the observation that B cells producing OAS Abs are
potentially precursors for B cells that produce more cross-reactive Abs, suggests that
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OAS Abs play an important role in protecting the host against secondary encounters with
antigenically drifted viral strains.
Materials and Methods
Animal Experiments
All murine experiments were performed at the Wistar Institute according to
protocols approved by the Wistar Institute Institutional Animal Care and Use Committee.
All mice were BALB/c strain female mice of at least 7 weeks of age.
Viruses
Viruses were grown in 10-day old fertilized chicken eggs and the HA genes of
each virus stock were sequenced to verify that additional mutations did not arise during
propagation. S12a has an additional K144E HA mutation compared to the previously
published Seq12 virus (Das et al., 2013). Seq12 viruses possessing the K144E HA
mutation grow efficiently in fertilized chicken eggs without acquiring additional HA
mutations. Some virus mutants were generated by reverse genetics as previously
described (Martínez-Sobrido and García-Sastre, 2010). Selected mutations were added
to the HA gene in a pDZ plasmid using a QuikChange II XL site-directed mutagenesis kit
(Agilent). As controls, we used B/Lee/1940 and the A/Puerto Rico/08/1934-J1 strain that
has an H3 HA from A/Hong Kong/01/1968.
HAU Assays
To determine the hemagglutination unit (HAU) titer of each viral prep, viruses
were diluted 2-fold across a 96-well round bottom plate (BD) and mixed with 12.5ul of
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2% (vol/vol) turkey erythrocytes (Lampire) in phosphate-buffered saline (PBS) (Cellgro).
Agglutination was read out after incubating for 60 minutes at room temperature.
50% Tissue Culture Infectious Dose (TCID50) Assays
96-well flat bottom plates (BD) were incubated overnight with 4e4 Madin Darby
canine kidney (MDCK) cells/well in minimum essential medium (MEM) (Cellgro) with 9%
fetal bovine serum (FBS) (Sigma). Plates were washed 3 times with serum-free MEM.
Viruses were diluted 10-fold across the plate in MEM supplemented with 0.1%
gentamicin (Gibco), 1ug/ml L-(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK)treated trypsin (Worthington), and 5 mM 2-[4-(2-hydroxyethyl)piperazin-1yl]ethanesulfonic acid (HEPES) (Cellgro).
HAI Assays
Sera were collected from mice by submandibular bleeding into 1.1ml Serum Gel
Z microtubes (Sarstedt) using a 5 mm lancet (Medipoint). Sera were then heat treated
for 30 minutes at 55C. HAI titrations were performed in 96-well round bottom plates.
Sera were serially diluted 2-fold in PBS and added to 4 agglutinating doses of virus in a
total volume of 100 µL. Turkey erythrocytes were added [12.5 µL of a 2% (vol/vol)
solution]. The erythrocytes were gently mixed with sera and virus and agglutination was
read out after incubating for 60 min at room temperature. HAI titers are expressed as the
inverse of the highest dilution that inhibited 4 agglutinating doses of virus.
ELISA
Viruses for ELISAs were inactivated by B-Propiolactone (BPL; Sigma-Aldrich)
treatment. Viruses were incubated with 0.1% BPL and 0.1 M HEPES overnight at 4C
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followed by a 90 minute incubation at 37C. 96-well Immulon 4HBX flat-bottom microtiter
plates (Fisher Scientific) were coated with 20 HAU per well BPL-treated virus overnight
at 4C. Plates were then incubated with 150ul 3% bovine serum albumin (BSA) (Sigma)
in PBS for 2 hours at room temperature. For initial hybridoma screening, hybridoma
supernatants were diluted 1:5 and then added to ELISA plates. For Ab footprint
mapping, purified mAbs were added at a starting concentration of 1 to 10 ug/ml and
diluted 2-fold across the plate. As a positive control, we used the stalk-reactive C179
mAb (Clontech). As a negative control and to assure that mAbs bound to HA, we used
the J1 virus strain which has an H3 HA. mAbs were incubated on the plates for 2 hours
at room temperature. mAb binding was measured by a secondary goat anti mouse IgG
or IgM Ab conjugated to alkaline phosphatase (Southern Biotech) incubated for 1 hour at
room temperature. Plates were developed with 100ul/well of a 2.7mM p-nitrophenyl
phosphate (PNPP) (Thermo Scientific) 0.1M NaHCO3 (Sigma-Aldrich) 1mM MgCl2
(Fisher Scientific) pH 9.8 solution. Absorbance was measured at 405nm. Plates were
washed with distilled water between each incubation step.
Hybridoma production
Some mice were first primed with 1000 HAU of virus with an i.p. injection and
boosted 28 days later with 1000 HAU of virus with an i.v. injection. 3 days later,
splenocytes from these mice were fused with SP2/0 cells using Polyethylene glycol
(Hybrimax 50% (w/v) Sigma-Aldrich). Some mice were primed only once i.v. with 1000
HAU of virus and splenocytes from these mice were fused 5 days later. Fused cells
were incubated in 5.7uM azaserine and 100uM hypoxanthine (Azaserine-hypoxanthine
Sigma-Aldrich) with 10% FBS in Dulbecco’s modified eagle medium (DMEM) (Cellgro).
10 days later hybridomas were screened by ELISA as described above. Positive clones
32

were subcloned by limiting dilution, and then grown in DMEM supplemented with Zap
hybridoma (InVitria). mAbs were purified using PureProteome A/G coated magnetic
beads (Millipore). For mAb transfer experiments, mAbs underwent buffer exchange into
PBS using Zeba desalt spin columns (Thermo Scientific).
mAb transfer experiments
25 ug of purified mAbs diluted in PBS were transferred into female BALB/c mice
(Charles River Laboratories) in a 200ul i.p injection. 12 hours later, mice were
challenged intranasally with a dose of 30 TCID50 of either PR8 or S12a in 50ul PBS.
For intranasal infections, mice were first anesthetized by inhalation of isoflurane (Henry
Schein). Weight was measured daily for 14 days.
Immunoglobulin sequencing
DNA was isolated from hybridoma clones using a Gentra Puregene cell kit
(Qiagen). Immunoglobulin heavy and light chain genes were amplified by PCR using a
Platinum Taq DNA Polymerase High Fidelity kit (Thermo Fisher Scientific) using
previously described primers (Ramsden et al., 1994; Wang et al., 2000). Amplified DNA
was run on a 1% agarose (Lonza) in TAE buffer (Corning) gel and DNA was purified
from the gel using a Zymoclean gel DNA recovery kit (Zymo Research). DNA fragments
were then sequenced by Sanger sequencing. For hybridomas whose productive and
non-productive rearrangements were not easily separated by gel electrophoresis, the
DNA was subcloned using a TOPO TA Cloning kit with the pCRII-TOPO vector
(Invitrogen).
mAb selection assay
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To select for viral escape mutants to selected mAbs, 96 well flat bottom plates
were coated with 4e4 MDCK cells/well in MEM with 9% FBS and incubated overnight at
37C. Virus used in this assay had been serially passaged in eggs a minimum of three
times to increase mutant frequency. Virus was incubated with four different
concentrations of virus to determine a saturating concentration of mAb for one hour at
room temperature. MDCK cell-coated plates were washed four times with serum free
MEM and 100ul of the virus/mAb mixture were transferred to the cells and incubated for
two hours at 37C. Plates were subsequently washed and coated with 100ul of MEM
with 0.1% gentamicin, 1ug/ml TPCK-treated trypsin, and 5 mM HEPES supplemented
with mAb. Plates were incubated for three days at 37C. At this time, cytopathology was
determined and virus collected from the infection endpoints of those wells that had a
saturating mAb concentration. vRNA was collected using a QIAamp viral RNA kit
(Qiagen) and sequenced to determine the mutation that enabled escape of mAb
mediated neutralization. Virus escape mutants collected were subsequently generated
by reverse genetics, or were subcloned by viral plaque assay. As a control, cells were
incubated with virus but without mAb to determine the mutant frequency in the viral
population.
Viral plaque assay
To subclone virus, 6 well plates (BD) were coated with 5e5 MDCK cells/well in
MEM with 9% FBS and incubated overnight at 37C. Plates were washed four times with
MEM and coated with 500ul serially diluted virus in MEM. Plates were incubated at 37C
for 1 hour with plates rocked every 15 minutes. Plates were washed with MEM and
coated with 1.6% agarose in MEM with 10mM HEPES, 0.1% gentamicin, 1ug/ml TPCK-
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treated trypsin, and 0.05% phenol red. Three days post infection, isolated plaques were
collected, confirmed by sequencing, and grown in 10 day old fertilized chicken eggs.
Statistical analyses
Student’s t tests, Fisher’s exact tests, area under the curve analyses, standard
deviation (SD), and standard error of the mean (SEM) were calculated using Graphpad
Prism6 software (Graphpad Software Inc).
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Figure 1. PR8 and S12a are antigenically distinct H1N1 viruses.
(A) PR8 and S12a differ at 13 HA residues (highlighted in black) (Protein database:
1RVX). The Sa, Sb, Ca, and Cb antigenic sites are shown in green, purple, blue, and
red respectively. (B,C) Mice were immunized i.p. with 1000 HAU PR8 or S12a virus.
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Sera were collected 21 days post-vaccination and HAI assays were completed using
PR8 (B) or S12a (C) virus. Data are mean +/- SD (*p < 0.0001; Student’s t test).
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Figure 2. S12a efficiently boosts Abs that react to PR8 HA.
(A,B) Seven week old BALB/c mice were immunized i.p. with 1000 HAU of PR8 or PBS
(X) and boosted 28 days later i.v. with 1000 HAU PR8, 1000 HAU S12a, 1000 HAU
B/Lee, or PBS (X) (n = 4 mice per group). Sera were collected at different times after
immunization and HAI assays were completed using PR8 (A) and S12a (B) viruses.
Data are mean +/- SEM. Mice boosted with both PR8 or S12a had significantly higher
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PR8 HAI titers compared with mice boosted with PBS (X) or the antigenically unrelated
B/Lee virus (p < 0.05; Student’s t test).
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Figure 3
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Figure 3. S12a boosts PR8 Abs at late time points after initial exposure.
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PR8 or PBS (X). Mice were boosted i.v. with
1000 HAU PR8, S12a, or B/Lee 28 days later.
Sera were collected 21 days after the boost
and tested by ELISA against PR8 virus. Sera

Student’s t test). (B) Mice were immunized i.p. with 1000 HAU PR8 or PBS (X). Mice
were boosted i.v. with 1000 HAU PR8, S12a, or B/Lee 28 days later. Sera were
collected 21 days after the boost and tested by ELISA against PR8 virus. Sera from mice
that were boosted with PR8 or S12a had significantly higher PR8 titers than mice that
were boosted with negative controls PBS or B/Lee (p < 0.05; Student’s t test of area
under the curve).
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Figure 4
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Figure 4. PR8-S12a sequential exposure elicits many Abs with a classical OAS
phenotype.
(A, B) Mice were immunized i.v. with 1000 HAU of PR8 (A) or S12a (B) virus.
Hybridomas were created from splenocytes collected 5 days after vaccination. (C, D)
Mice were immunized i.p. with 1000 HAU of PR8 and boosted i.v 28 days later with 1000
HAU PR8 (C) or S12a (D). Hybridomas were produced 3 days after the boost. We
completed ELISAs with a range of different mAb concentrations using plates coated with
PR8, S12a, and J1 (J1 is a virus that has an H3 HA). mAbs were determined to be PR8
and/or S12a-specific if they produced an ELISA signal that was 4 times greater using
PR8 or S12a coated plates compared to plates coated with the J1 negative control.
Mice boosted with S12a had a higher proportion of Abs cross-reactive for both PR8 and
S12a (p < 0.005; Fisher’s exact test).
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were isolated from mice exposed to PR8. (B) 125 mAbs were isolated from mice
exposed to S12a. (C) 50 mAbs were isolated from mice sequentially exposed to PR8
twice. (D) 86 mAbs were isolated from mice sequentially exposed to PR8 and S12a. We
did not use many mice for PR8 primary exposure since previous studies have
characterized mAbs isolated from mice following a single PR8 exposure.
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S3 Fig. Most ‘cross-reactive’ mAbs bind better to PR8 compared to S12a.
(A-C) mAbs were tested by ELISA for reactivity against PR8, S12a, and J1 virus. Shown are 3 mAbs that
bound with
higher ‘cross-reactive’
relative affinity to PR8mAbs
than to S12a.
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we used the
Figure
6. aMost
bind As
better
to PR8
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to S12a.
stalk-specific C179 mAb that bound with similar affinities to both PR8 and S12a (not shown).

(A-C) mAbs were tested by ELISA for reactivity against PR8, S12a, and J1 virus. Shown
are 3 mAbs that bound with a higher relative affinity to PR8 than to S12a. As an ELISA
coating control, we used the stalk-specific C179 mAb that bound with similar affinities to
both PR8 and S12a (not shown).
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S4 Fig. ‘OAS’ mAbs bind very poorly to S12a.
(A-C) mAbs were tested by ELISA for reactivity against PR8, S12a, and J1 virus. Shown are three mAbs
elicited in mice that received a PR8-S12a prime-boost vaccination that had measurable binding to PR8 but
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(A-C) mAbs were tested by ELISA for reactivity against PR8, S12a, and J1 virus. Shown
are three mAbs elicited in mice that received a PR8-S12a prime-boost vaccination that
had measurable binding to PR8 but not to S12a. As an ELISA coating control, we used
the stalk-specific C179 mAb that bound with similar affinities to both PR8 and S12a (not
shown).
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Figure 8. Fine specificity of mAbs elicited by sequential H1N1 exposure.
(A, B) mAbs created from PR8 pre-exposed mice that were boosted either with PR8 (A)
or S12a (B) were tested for binding to a panel of viruses by ELISA. We first completed a
dose titration of each mAb on ELISA plates coated with PR8. We determined the lowest
concentration of each mAb at which PR8 ELISA signal was within 90% of Bmax, and we
tested this mAb concentration against all of the mutant viruses. The shade of color in
each square is relative to the percentage of binding to that virus compared to PR8
binding with the darkest color being 100% and white being 0%. The coloring scheme
(Sa=green, Sb=purple, Ca=blue, Cb=red) matches the coloring scheme of the HA
structure shown in Figure 1.
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Figure 9. The HA Ab response is focused on the Sb antigenic site following
(A-B) Hybridomas derived from mice that were vaccinated with PR8 virus and boosted 28 days later with
either PR8 (A) or S12a (B) were predominantly specific for the Sb antigenic site.
sequential
(C-D)This
wasexposure.
in contrast to hybridomas derived from mice that were immunized only with PR8 (C) or
S12a (D) (p < 0.05; Fisher’s exact test).

(A-B) Hybridomas derived from mice that were vaccinated with PR8 virus and boosted
28 days later with either PR8 (A) or S12a (B) were predominantly specific for the Sb
antigenic site. (C-D) This was in contrast to hybridomas derived from mice that were
immunized only with PR8 (C) or S12a (D) (p < 0.05; Fisher’s exact test).
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Figure 10
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H5 51D
H5 60A
H5 50B
H5 61B
H4 S27B
H4 S10B
H13 S1 3C
H13 S1 5B
H13 S1 1C
H13 S1 8A
H13 S1 2B
H13 S1 9C
H13 S1 6A
H13 S1 4A
H2 S95A
H5 74A
H5 44A (IgM)
H5 65A
H2 S34D
H13 S2 25A
H13 S2 29C
H4 S32B

PR8
S188I
L194I
N187H
G159S
I217K
E190K
E198G
Q192R
Q196R
E156K
N193K
K189N
S12a
J1

expanded Sb mutant panel

expanded Sb mutant panel

mAb
H4 P22C (IgM)
H4 P12C (IgM)
H4 P39A (IgM)
H4 P2A
H4 P31B
H4 P36A
H13 P2 2B
H13 P1 7A
H9 S2 7D
H2 P3A
H4 P41B
H13 P1 4D
H5 36B
H13 P2 3B
H13 P1 2C
H5 10B
H2 P4A
H5 19B
H13 P1 6C
H13 P2 5B
H13 P1 3B
H5 22A
H5 25B
H5 32C
H2 P9A
H13 P1 5B
H5 12A
H9 S2 4B
H5 20B
H4 P38C (IgM)
H9 S2 6C

C

B PR8-S12a elicited mAbs

PR8-PR8 elicited mAbs

PR8
S188I
L194I
N187H
G159S
I217K
E190K
E198G
Q192R
Q196R
E156K
N193K
K189N
S12a
J1

A

D
other Sb residues tested

156

S6 Fig. Fine mapping of Sb mAbs reveals that most cross-reactive mAbs are not
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sensitive to an E156K HA mutation.
(A, B) mAbs that were derived from mice immunized with PR8 and then boosted 28 days later with
either PR8 (A) or S12a (B) were tested for binding to a panel of viruses. Twelve of these viruses
had single point mutations at residues in and around the previously defined Sb site. Most
S12a-reactive mAbs that were elicited by PR8-S12a sequential exposure were resistant to an
E156K HA mutation (highlighted in red). More E156K-resistant mAbs were derived from PR8-S12a
exposed mice compared to PR8-PR8 exposed mice (highlighted in red).
(C, D) The locations of the point mutations tested in Figure S6A-B are highlighted in green on the

Figure 10. Fine mapping of Sb mAbs reveals that most cross-reactive mAbs are
not sensitive to an E156K HA mutation.
(A, B) mAbs that were derived from mice immunized with PR8 and then boosted 28 days
later with either PR8 (A) or S12a (B) were tested for binding to a panel of viruses.
Twelve of these viruses had single point mutations at residues in and around the
previously defined Sb site. Most S12a-reactive mAbs that were elicited by PR8-S12a
sequential exposure were resistant to an E156K HA mutation (highlighted in red). More
E156K-resistant mAbs were derived from PR8-S12a exposed mice compared to PR8PR8 exposed mice (highlighted in red). (C, D) The locations of the point mutations
tested in Figure S6A-B are highlighted in green on the HA structure shown from the side
(C) and from the top (D). Residue 156 is highlighted in red.
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Figure 11
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Figure 11. Most Sb mAbs elicited by PR8-S12a sequential exposure are not
sensitive to the E156K mutations and protect against PR8 and S12a infection.
(A, B) Sb-specific mAbs from mice pre-exposed to PR8 virus and boosted with either
PR8 (A) or S12a (B) virus were tested for binding by ELISA to PR8 viruses +/- the
E156K HA mutation. mAbs that bound to the E156K mutant >25% relative to PR8 were
considered ‘E156K-resistant’. PR8-S12a exposure elicited a higher proportion of
‘E156K-resistant’ mAbs compared to PR8-PR8 exposure (p < 0.0001; Fisher’s exact
test). (C, D) 25ug of the H2-S37B or H4-S10B mAbs were transferred i.p. into mice 12
hours before infection with 30 TCID50 of PR8 (C) or S12a (D) virus. Weight loss was
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measured for 14 days post-infection. PR8-infected mice that received either mAb lost
significantly less weight than mice that received a PBS control (no mAb) (p < 0.05 at
days 3-14 for H2 S37B, p < 0.05 at days 6-14 for H4 S10B; Student’s t test). S12ainfected mice that received the H4-S10B mAb lost significantly less weight than mice
that received a PBS control (p < 0.05 at days 7-9; Student’s t test). Data are mean +/SEM.
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Figure 12
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32

32

Figure 12. Somatic mutations affect binding to both PR8 and S12a.
(A-F) Six clonally related (see Table S1) IgG2a mAbs derived from a mouse primed with
PR8 and boosted with S12a were tested for binding to PR8, S12a, and the antigenically
unrelated J1 virus via ELISA (J1 is a virus that has an H3 HA). Data are mean +/- SEM.
(G) As an ELISA coating control, the H1 stalk-reactive C179 mAb was tested for binding
to PR8, S12a, and J1 virus. Data are mean +/- SEM.
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Figure 13
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Figure 13. mAbs elicited by PR8-S12a immunization prevent disease caused by
PR8 and S12a infections.
(A, B) 25ug of different mAbs were transferred i.p. into mice 12 hours before infection
with 30 TCID50 PR8 (A) or S12a (B) (n=5 mice per group). PR8-infected mice that
received H5-42B, H5-61B, or the PR8 primary mAb lost significantly less weight than
mice that received a PBS control (no mAb) (p < 0.05 at days 5-14 for H5-42B, p < 0.05
at days 6-14 for H5-61B, p < 0.05 at days 8-10 for the PR8 primary mAb; Student’s t
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test). S12a-infected mice that received the H5-42B, H5-61B, or S12a primary mAb lost
significantly less weight than mice that did not receive mAbs (p < 0.05 at days 8-12 for
H5-42B, p < 0.05 at days 6-12 for H5-61B, p < 0.05 at days 6-14 for S12a primary mAb;
Student’s t test). (C) Sera was collected 12 hours after mAb transfer and tested by HAI
assay against PR8 and S12a virus (n=3 mice per group). Data are mean +/- SEM.
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Table 1

H5-61B

29
ACT
T
---

H5-42B

---

CDR1
35
37
AGT
TAT
S
Y
---TF
-----

H5-49B

---

---

---

---

---

---

---

H5-51D

---

---

---

--T

--C

--T

--A

H5-60A

---

--C

-TF
-TF
-TF

---

H5-50B

T-S
---

---

--A

-CT
---

C-H
C-H

AA residue
germline

38
TAC
Y
---

FR2
49
AGG
R
--A

CDR2
63
AGT
S
---

---

---

---

66
TAC
Y
C-H
---

72
AAG
K
C-Q
C-Q
C-Q
C-Q
C-Q
C-Q

75
CGA
R
----------C
---

FR3
84
AAG
K
-GR
-GR
-GR
-GR
-GR
-GR

85
AAC
N
---

88
TAC
Y
---

92
AGC
S
---

---

---

---

-TF
---

---

---

---

GG G
---

---

-CT
---

---

---

CDR3
106
108
AGA
GAC
R
N
--G
A-T

115
ATG
M
---

--G

A-T

---

--G

A-T

---

--G

A-T

---

---

--G

A--

---

---

--G

A--

T-L

105
GCA
A
-TV
T-S
-TV
---

Table 1: Identification of a clonally related family of mAbs.

Mutations that differ each mAb in the framework regions (FR) or complementaritydetermining regions (CDR) from the heavy chain germline sequence (IGHV5-4*02,
IGHD2-14*01, IGHJ4*01) are shown using IMGT (International immunogenetics
information system) numbering (Giudicelli et al., 2011). FR1 was not determined
because the sequencing primer bound to this region. We also sequenced the CDR3
region of the light chain (IGKV8-28*01, IGKJ5*01) which was identical between all 6
mAbs.
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CHAPTER 3: POTENTIAL ANTIGENIC EXPLANATION FOR
ATYPICAL H1N1 INFECTIONS AMONG MIDDLE-AGED ADULTS
DURING THE 2013-2014 INFLUENZA SEASON
Summary
Influenza infections usually cause more severe disease in very young or elderly
individuals. Intriguingly, H1N1 influenza infections caused an unusually high disease
burden in middle-aged adults during the 2013-2014 influenza season. We hypothesize
that this may be due to increased sensitivity of middle-aged adults to a new mutation
that had recently been acquired by nearly all contemporary circulating H1N1 strains. To
test this hypothesis, we tested sera from healthy human blood donors from different age
groups against the newly mutated strain. Interestingly, we found that over 42% of
individuals born between 1965 and 1979 exhibited reduced binding to the new mutated
strain compared to the previously circulating strain. This was in stark contrast to
younger individuals born between 1985 and 1997 who exhibited no reduction in titers
against the newly mutated strain. We also found that mAbs isolated from middle-aged
adults that bound to this epitope failed to protect mice from infection of the newly
mutated strain. We show examples of middle-aged individuals who develop this
particular specificity after immunization with the previously circulating strain and in
ferrets sequentially exposed to strains relevant to middle-aged adults. This suggests
that while sequential exposure shifts the Ab response to more conserved sites, this may
ultimately lead to increased susceptibility when viral mutations in these sites occur.
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Introduction
In the previous chapter, we have shown in a mouse model that sequential
exposure to antigenically drifted strains of influenza virus elicits an increased proportion
of cross-reactive Abs and that the specificity of mAbs shifts towards more conserved
epitopes that are less sensitive to mutations that differ between the strains. Surprisingly,
we also found that even OAS Abs that bind with a higher affinity to the priming strain can
provide modest protection against influenza infections and may be precursors to more
cross-reactive Abs though somatic hypermutation.
Unfortunately, influenza viruses are constantly mutating, and humans are
potentially exposed to antigenically drifted viral strains on an annual basis. Shifts in
epitope immunodominance have been shown to occur due to pre-exposure history (Li et
al., 2013). As individuals from different age groups have different pre-exposure histories
due to the persistent change in circulating viral populations, we hypothesize that this
may explain why different age groups have different influenza virus-specific Ab
repertoires. This suggests that while OAS Abs can have positive protective qualities due
to limited cross-reactivity between two strains, the gradual shift of the Ab response to
momentarily conserved epitopes may also lead to increased susceptibility should a virus
arise that has mutations that abrogate Ab binding to a previously conserved region.
Results
An HA mutation acquired prior to the 2013-2014 influenza season is antigenically
relevant in middle-aged adults
While the H1N1 component of the vaccine was not updated for the 2013-2014
season, mutations have been accumulating in circulating pH1N1 strains since the virus
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arose in 2009 (Figure 14C). A K166Q mutation located on the distal head of the HA that
was first sequenced from viral isolates in the 2012-2013 season became rapidly fixed in
the circulating viral population (Figure 14A-B). This mutation has previously been
considered antigenically neutral based on experiments using primary antisera from
ferrets infected with the 2009 pH1N1 strain (Arriola, 2014). However, the antigenicity of
this region may have been underrepresented by these experiments as primary antisera
to the pH1N1 strain have been shown to be focused to other regions of the HA,
particularly those epitopes containing residues 156, 157, and 158 (Chen et al., 2010; Li
et al., 2013). The amino acids at residues 156, 157, and 158 have not been extensively
mutated in pH1N1 strains circulating between 2009 and 2014 (Figure 15). In contrast to
the ferrets used in surveillance experiments, humans are sequentially exposed to
antigenically drifted strains throughout their lives. To test whether human sera binds to
this newly mutated epitope, we tested sera collected from healthy human blood donors
during the 2013-2014 influenza season by HAI against the wild type (WT) pH1N1 strain,
and a pH1N1 strain engineered to contain the newly acquired K166Q mutation.
Interestingly, we found that 27% of sera from individuals born between 1940 and 1984
had at least a twofold reduction in titers to the new mutant virus when compared to the
WT strain. Remarkably, over 42% of individuals born from 1965 to 1979 (n = 54
individuals) also demonstrated this reduction. This is in contrast to younger individuals
born from 1985 to 1997 (n = 49 individuals) who did not have a measurable decrease in
serum titers to the newly mutated strain (Figure 16A, Table 2). This difference in K166
specificity between these two age groups was statistically significant (p < 0.0001;
Fisher’s exact test). Similar results were obtained when we tested sera from healthy
human adults collected during the 2013-2014 influenza season in Mexico (Figure 17,
Table 3).
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The difference in K166 epitope immunodominance is due to unique pre-exposure history
We hypothesize that the difference between these two age groups is due to a
difference in pre-exposure history. We propose that the Abs elicited in middle-aged
adults that are specific for this newly mutated epitope were elicited by previously
circulating sH1N1 strains circulating in humans before 1985 and then recalled by the
2009 pH1N1 strain. sH1N1 strains that circulated in the late 1970s and early 1980s
share extensive homology with the pH1N1 strain (Figure 16B) and H1N1 strains did not
circulate in humans from 1957 to 1976, so adults born after 1957 would have been
potentially exposed to H1N1 strains as early as 1977. In contrast, sH1N1 strains
acquired a mutation that introduced a glycosylation site at HA residue 129. This
glycosylation site blocks binding of K166-specific mAbs (Linderman et al., 2014). We
hypothesize that K166 epitope specific Abs were not elicited by seasonal strains
circulating after 1985 when the glycosylation site that shields this epitope was introduced
and so were not recalled by infection or immunization with the pH1N1 strain that lacks
this glycosylation. To test our hypothesis that sequential exposure to strains circulating
before 1985 and the 2009 pH1N1 strain affected the prevalence of K166-specific Abs,
we tested sera from humans born before 1984 that was collected before and after
vaccination with the 2009 pH1N1 strain. As these sera were collected in 2009, most
individuals did not have measurable titers to the 2009 pH1N1 strain before vaccination.
Sera from 5 out of 17 individuals demonstrated a measurable increase in K166 epitope
specific titers after vaccination with the 2009 pH1N1 (Figure 18A, Table 4). We also
measured binding of 42 head specific mAbs collected from 12 adult donors (born 19491985) that were vaccinated with the pH1N1 strain in 2009. Remarkably, 23% of these
mAbs had reduced binding to a pH1N1 K166Q mutant virus compared to the WT 2009
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pH1N1 strain (Figure 18B). We hypothesize that these Abs were previously elicited by
seasonal strains and recalled by the 2009 pH1N1 vaccination. To test this in a more
controlled animal model, we sequentially infected ferrets with sH1N1 strains that
circulated in 1977, 1983, or 1986, followed by infection with the 2009 pH1N1 strain. As
controls, we infected previously naïve ferrets with the 2009 pH1N1 strain and also
sequentially infected ferrets with the 2009 pH1N1 strain twice. Three out of eight ferrets
that were infected with the pH1N1 strain after pre-exposure to the A/Chile/01/1983 virus
had detectable K166 specific titers (Figure 19, Table 5). This was in contrast to ferrets
pre-exposed to the A/Singapore/06/1986 strain which has a glycosylation site that is
predicted to shield the region around residue 166, as well as ferrets pre-exposed to the
A/USSR/90/1977 strain. The A/USSR/90/1977 - A/California/07/2009 strain likely did not
recall K166 HA specific mAbs because of variation at residue 125, which is in close
proximity to residue 166 (Figure 20). Neither ferrets that received one pH1N1 infection
or two sequential pH1N1 infections elicited detectable K166 HA specific titers.
K166 HA-specific Abs are less effective against K166Q HA mutant virus infection
In the previous chapter, we showed that even Abs with low affinity for a mutated
strain could protect against infection. We passively transferred a K166 HA specific mAb
(SFV009—3F05) or a control mAb that binds equally well to the K166Q HA mutant and
WT strains (SFV015-1F02) to BALB/c mice 12 hours prior to infection with the WT
pH1N1 strain or a K166Q HA mutant strain (Figure 18C). While both mAbs protected
against the WT pH1N1 strain, the K166 HA specific mAb failed to protect mice against
infection with the K166Q HA mutant strain. In addition, we tested human sera by in vitro
neutralization assay. Sera that had K166 HA specificity based on HAI assays failed to
efficiently neutralize K166Q HA mutant viruses (Table 6). This suggests that K166 HA
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specific Abs can be less effective at preventing disease. As we have shown that these
types of mAbs are more common in middle-aged adults, this offers a potential antigenic
explanation for the increased disease burden in middle-aged adults that occurred during
the 2013-2014 influenza season.
Discussion
Our studies suggest that an HA mutation that was first recognized during the
2012-2013 influenza season is antigenically relevant and potentially physiologically
relevant in a subset of the population. The antigenic change caused by the K166Q HA
mutation may have been previously overlooked as primary ferret sera to the pH1N1
strain do not represent the influenza-specific Ab repertoire in humans who are exposed
to influenza viruses repeatedly throughout life. To complicate matters, since influenza
viruses are constantly mutating, individuals from different age groups have unique preexposure histories. We hypothesize that this affects the influenza-specific Ab repertoire
and may explain the unusually high level of disease in middle-aged adults during the
2013-2014 influenza season. We have shown here that the K166Q HA mutation
abrogates binding of Abs prevalent in middle-aged adults. Previous studies have shown
that sequentially infecting ferrets with antigenically drifted strains of influenza shifts the
influenza-specific Ab response to focus on different epitopes (Li et al., 2013). We have
recapitulated this and found that some ferrets pre-exposed to a previously circulating
seasonal strain elicit a strong Ab response against this newly mutated region of the HA.
In addition, we have found that vaccination with the pH1N1 strain can increase the titers
of Abs of this specificity. These Abs have reduced neutralization capabilities against the
newly mutated strain. This suggests that surveillance of influenza viruses should take
into account the effect of pre-exposure history on the influenza-specific Ab repertoire
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when considering whether a new mutation that arises in the circulating viral population
constitutes an antigenic change. In addition, these studies suggest that pre-exposure
history not only affects the Ab repertoire, but may also affect susceptibility to influenza
infection.
Materials and Methods
Human Donors
Studies involving human adults were approved by the Institutional Review
Boards of Emory University, Vaccine and Gene Therapy Institute of Florida, the National
Institute of Respiratory Diseases of Mexico, and the Wistar Institute. Informed consent
was obtained. For all experiments, HAI and in vitro neutralization assays were
completed at the Wistar Institute using preexisting and de-identified sera. We analyzed
several serum panels in this study. We analyzed sera from healthy donors collected at
the New York Blood Center in February of 2014. We analyzed sera from healthy donors
collected at the Center for Research in Infectious Diseases at the National Institute of
Respiratory Diseases in Mexico. We analyzed sera and mAbs derived from healthy
donors vaccinated with a monovalent pH1N1 vaccine in 2009 as previously described (Li
et al., 2012).
Viruses
Viruses possessing WT pH1N1 HA or K166Q pH1N1 HA were generated via
reverse-genetics using HA and NA genes from A/California/07/2009 and internal genes
from A/Puerto Rico/08/1934. All of these viruses were engineered to possess the
antigenically neutral D225G HA mutation, which facilitates viral growth in fertilized
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chicken eggs (Chen et al., 2010). Viruses were grown in fertilized chicken eggs and the
HA genes of each virus stock were sequenced to verify that additional mutations did not
arise during propagation. sH1N1 strains (A/USSR/90/1977, A/Chile/01/1983,
A/Singapore/06/ 1986, A/Texas/36/1991, A/New Caledonia/20/1999, and A/Solomon
Islands/03/2006) were also grown in fertilized chicken eggs. We isolated a pH1N1 virus
from respiratory secretions obtained from a patient from the Children’s Hospital of
Philadelphia in 2013 (A/CHOP/1/13). For this process, de-identified clinical material from
the Children’s Hospital of Philadelphia Clinical Virology Laboratory was added to MDCK
cells (originally obtained from the National Institutes of Health) in serum-free media with
TPCK-treated trypsin (Worthington), HEPES (Cellgro), and gentamicin (Gibco). Virus
was isolated from the MDCK-infected cells 3 days later. We extracted viral RNA and
sequenced the HA gene of A/CHOP/1/13.
Animal Experiments
Murine experiments were performed at the Wistar Institute according to protocols
approved by the Wistar Institute Institutional Animal Care and Use Committee. BALB/c
mice (Charles River Laboratories) were injected with 25 µg of mAb i.p. and then infected
intranasaly with 20,000 TCID50 of WT or K166Q-HA pH1N1 virus 12 hours later. As
controls, some mice received an i.p injection of PBS (Cellgro) before infection. Weight
loss and survival was recorded for 11 days. Severely sick mice were euthanized. Ferret
experiments were performed at the Vaccine and Gene Therapy Institute of Florida in
accordance with the National Research Council’s Guide for the Care and Use of
Laboratory Animals, the Animal Welfare Act, and the CDC/NIH Biosafety in
Microbiological and Biomedical Laboratories handbook (Council, 2011). Fitch ferrets
(Marshall Farms) were infected with 1 × 106 PFU of sH1N1 virus and bled 14 and 84
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days later. These ferrets were then infected with the A/California/ 07/2009 pH1N1 strain
and bled 14 days later. Some ferrets were sequentially infected with
A/California/07/2009 (84 days between infections) and other ferrets were infected with
only A/California/07/2009 and bled 14 days later.
HAI Assays
Sera samples were pretreated with receptor-destroying enzyme (Key Scientific
Products or Sigma-Aldrich) and HAI titrations were performed in 96-well round bottom
plates (BD). Sera were serially diluted twofold and added to four agglutinating doses of
virus in a total volume of 100 µL. Turkey erythrocytes (Lampire) were added [12.5 µL of
a 2% (vol/vol) solution]. The erythrocytes were gently mixed with sera and virus and
agglutination was read out after incubating for 60 minutes at room temperature. HAI
titers were expressed as the inverse of the highest dilution that inhibited four
agglutinating doses of turkey erythrocytes. Each HAI assay was performed
independently on three different dates. Sera that had at least twofold reduced HAI titers
using K166Q HA mutant viruses in three independent HAI assays were labeled as “K166
HA-specific.”
ELISA
Viruses for ELISAs were concentrated by centrifugation at 20,000 RPM for 1
hour using a Thermo Scientific Sorvall WX Ultra 80 Centrifuge with a Beckman SW28
rotor. Concentrated viruses were then inactivated by BPL (Sigma-aldrich) treatment.
Viruses were incubated with 0.1% BPL and 0.1M HEPES overnight at 4C followed by a
90 minute incubation at 37 °C. The 96-well Immulon 4HBX flat-bottom microtiter plates
(Fisher Scientific) were coated with 20 HAU per well BPL-treated virus overnight at 4 °C.
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Each human mAb was serially diluted in PBS and added to the ELISA plates and
allowed to incubate for 2 hours at room temperature. As a control, we added the 701C04 stalk-specific mAb to verify equal coating of WT and K166Q HA virus. Next,
peroxidase conjugated goat anti-human IgG (Jackson Immunoresearch) was incubated
for 1 hour at room temperature. Finally, Sureblue TMB Peroxidase Substrate (KPL) was
added to each well and the re-action was stopped with addition of 250 mM HCl solution.
Plates were extensively washed with water between each ELISA step. Affinities were
determined by nonlinear regression analysis of curves of 6 mAb dilutions (18 µg/mL to
74 ng/mL) using Graphpad Prism. mAbs were designated as K166 specific if they had a
Kd at least four times greater for the K166Q mutant than for the WT virus.
In Vitro Neutralization Assay
Sera were serially diluted and then added to 100 TCID50 units of virus and
incubated at room temperature for 30 minutes. The virus-serum mixtures were then
incubated with MDCK cells for 1 hour at 37 °C. Cells were washed and then serum-free
media with TPCK-treated trypsin was added. Endpoints were determined visually 3 days
later. Data are expressed as the inverse of the highest dilution that caused
neutralization. All samples were repeated in quadruplicate and geometric mean titer is
reported.
Structural Modeling of HA Glycosylation Sites
Glycans were modeled onto positions 129 and 131 in the A/Solomon
Islands/03/2006 HA crystal structure (PDB ID code 3SM5) using the GLYCAM Web
Glycoprotein Builder (www.glycam.org). The particular glycan used for modeling was an
N-linked glycan with a trimannosyl core (DManpa1-6[DGlcpNAcb1-2DManpa167

3]DManpb1-4DGlcpNAcb1- 4DGlcpNAcb1-OH in Glycam notation), and default rotamer
settings were used for modeling. To model the 131 glycosylation site, a T131N mutation
was introduced using the PyMol structure viewer before the structure was uploaded to
the GLYCAM-Web server.
Computational and Phylogenetic Analyses of HA Sequences

The occurrence of different amino acid identities at HA residues 166, 156, 157,
and 158 (H3 numbering) was analyzed by downloading all full-length human pandemic
H1N1 sequences present in the Influenza Virus Resource as of February 23, 2014 (Bao
et al., 2008). After purging sequences that were less than full length, contained
ambiguous nucleotide identities, lacked full (year, month, day) isolation dates, or were
otherwise anomalous, the sequences were aligned. Each calendar year was broken into
four equal partitions beginning with January 1, and the frequencies of different amino
acids at each residue of interest for each partition was calculated and plotted. Only
amino acids that reached a frequency of at least 1% in at least one of the year partitions
are labeled in the legend to the plot. For construction of phylogenetic trees, the
sequence set was randomly subsampled to 10 sequences per quarter-year partition.
BEAST was then used to sample from the posterior distribution of phylogenetic trees
with reconstructed sequences at the nodes, after date stamping the sequences, using a
JTT with a single rate category with an exponential prior, a strict molecular clock, and
relatively uninformative coalescent-based prior over the tree (Drummond et al., 2012;
Jones et al., 1992). Fig. 1C shows a maximum clade credibility summary of the
posterior distribution with branches colored according to the reconstructed amino acid
identity at site 166 with the highest posterior probability at their descendent nodes. The
tree was visually rendered using FigTree. The input data and computer code used for
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this analysis can be found on GitHub at github.com/jbloom/pdmH1N1_
HA_K166_mutations.

Statistical Analyses
For all serum experiments, we excluded samples that did not have positive
pH1N1 HAI titers. All samples that were pH1N1 HA-WT HAI negative were also pH1N1
HA-K166Q HAI-negative. Samples were allocated to specific groups based on age of
donor. The year of birth of each sample was available during the experiment, but this
information was not assessed until each experiment was completed. Variance of raw
HAI titers was similar between different age groups. Fisher’s exact tests were completed
using SAS v9.3 software.
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Figures and Tables
Figure 14
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Figure 14. pH1N1 viruses rapidly acquired HA mutation K166Q during the 2013–
2014 influenza season.
(A) Residue K166 (red) is shown on the A/California/04/2009 HA trimer [PDB ID code
3UBN (Xu et al., 2010)]. (B) Plotted is the frequency of different amino acid identities at
HA residue 166 in pH1N1 HA sequences as a function of time. Nearly all pH1N1
possessed K166 from 2009 to mid-2012, but most isolates possessed Q166 by the
2013–2014 season. (C) A phylogenetic tree of pH1N1 viruses with branches colored
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according to amino acid identity at site 166 illustrates the rapid fixation of K166Q in
recent pH1N1 isolates.
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Figure 15
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Figure 15. Sequence variation of pH1N1 HA.

The residues in the dominant antigenic site recognized by primary ferret anti-sera
(residues 156, 157, and 158 of the Sa antigenic site) are highly conserved in pH1N1 (A–
C). No variation greater than 1% occurred at residue 156 and very little variation
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occurred at residues 157 and 158. For comparison, residue 166 (D; also shown in Fig.
1B) has undergone a complete change in the last year.
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Figure 16
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Figure 16. Adult humans possess Abs that bind to a region of HA that was
recently mutated in pH1N1.
(A) Sera were isolated from healthy donors (n = 195) from the state of New York during
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the 2013–2014 influenza season. HAI assays were performed using viruses with either
WT A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation. For
each sera sample, we completed three independent HAI assays. Raw HAI data are
reported in Table 2. Percentages of samples that had at least a twofold reduction in HAI
titer using the mutant virus in three independent experiments are shown. K166 specificity
of sera from individuals born between 1965 and 1979 is statistically significant compared
with K166 specificity of sera from individuals born after 1985 (*p < 0.0001; Fisher’s exact
test). (B) Homology between the A/Chile/01/1983 sH1 and the A/California/04/2009 pH1
are shown using the crystal structure of the A/California/04/2009 HA [PDB ID code
3UBN (Xu et al., 2010)]. Residue K166 is colored green. Amino acids that differ between
A/Chile/01/ 1983 and A/California/04/2009 are shown in red. The glycan receptor is
shown in black.
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Figure 17
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Figure 17. Mexican donors born before 1985 possess Abs that bind to the region
of HA that was recently mutated in pH1N1.

Sera were isolated from healthy donors (n = 45) at the Center for Research in Infectious
Diseases at the National Institute of Respiratory Diseases in Mexico during the 2013–
2014 influenza season. HAI assays were performed using viruses with either WT
A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation. For
each sera sample, we completed three independent HAI assays. Raw HAI data are
reported in Table 3. Percentages of samples that had at least a twofold reduction in HAI
titer using the mutant virus in three independent experiments are shown. (*p < 0.05;
Fisher’s exact test).
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Figure 18

post

b mAb reactivity

c
weight
(% original)

90
80
70
60

post

#13

pre

post

PBS

pre

post

SFV009-3F05 mAb

1 3 5 7 9 11

80
70
60

WT

pre

K166Q

post

SFV015-1F02 mAb
100

100
90

#21

HAI titer

160
80
40
20
≤10

HAI titer

160
80
40
20
≤10

HAI titer

pre

100

WT+/K166Q+
WT+/K166Q -

#7

160
80
40
20
≤ 10

weight
(% original)

pre

#6

160
80
40
20
≤10

weight
(% original)

#1

HAI titer

160
80
40
20
≤10

HAI titer

a

1 3 5 7 9 11
days (post infection)

WT

90

K166Q

80
70
60

1 3 5 7 9 11

Figure 18. Vaccination of middle-aged adults with the current pH1N1 vaccine
strain elicits Abs that bind to a region of HA that is now mutated in most pH1N1
isolates.
(A) Healthy adult volunteers were vaccinated with a monovalent pH1N1 vaccine in
2009. Sera were isolated pre-vaccination and 30 days post-vaccination and HAI assays
were performed using viruses with either WT A/California/07/2009 HA or
A/California/07/2009 HA with a K166Q HA mutation. Shown are HAI titers for donors that
possessed K166 HA-specific Abs following vaccination. Data are representative of three
independent experiments. Raw HAI titers for all donors are shown in Table 4. (B)
ELISAs were completed using mAbs isolated from healthy adult volunteers that were
vaccinated with a monovalent pH1N1 vaccine in 2009. ELISAs were coated either with
A/California/07/2009 (WT) or A/California/07/2009 with a K166Q HA mutation. Shown
are percentage of mAbs that bound to both viruses and percentage of mAbs that bound
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to the WT virus but not the mutant virus (n = 42 mAbs). Data are representative of two
independent experiments. (C) A K166 HA specific mAb (SFV009-3F05) or a mAb that
recognizes both WT and K166Q HA pH1N1 (SFV015-1F02) were injected into BALB/c
mice (n = 4 per group). Twelve hours later, mice were then infected with 20,000 TCID50
of WT or K166Q HA virus and weight loss and survival were recorded for 11 days. Data
are representative of two independent experiments.
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Figure 19
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Figure 19. Ferrets sequentially infected with A/Chile/01/1983 and A/California/
07/2009 develop K166 HA specific Abs.
Ferrets were infected with a sH1N1 virus and then reinfected 84 days later with the
A/California/07/2009 pH1N1 virus. Sera were collected 14 days after the second
infection and HAI assays were completed using WT and K166Q-HA pH1N1 viruses.
Shown are percentages of samples that had at least a twofold reduction in HAI titer
using the K166Q HA mutant virus in three independent experiments. Raw HAI titers are
shown in Table 5. The difference in K166 HA specificity is statistically significant
comparing the A/Chile/01/1983-A/California/07/2009 group with the rest of the groups (3
of 8 vs. 0 of 22; p < 0.05; Fisher’s exact test).
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Figure 20

125 166

Figure 20. Homology between A/USSR/90/1977, A/Chile/01/1983, and
A/California/07/2009.

HA residues that differ between A/Chile/01/1983 and the A/California/ 07/2009 are
shown in red. A few additional HA residues differ between the HAs of A/USSR/90/1977
and A/California/7/2009, and these are colored yellow. Of note, A/Chile/01/1983 and
A/California/07/2009 both possess S125 whereas A/USSR/90/1977 possess R125.
Residues 125 and 166 are next to each other in the structure. PDB ID file 3UBN
(A/California/04/2009 HA) was used to make this figure.
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Table 2
sample ID

YOB

experiment #1
HAI titers
WT
K166Q

40-60
40-49
40-05
40-02
40-44
40-14
40-16
50-55
50-11
50-43
50-06
60-04
60-10
60-13
60-25
60-14
60-23
60-44
60-28
60-41
60-63
60-35
70-56
70-52
70-60
70-74
70-36
70-84
70-86
70-13
70-54
70-25
70-10
70-23
70-82
70-50
70-80
70-19
80-16
80-48

1940
1943
1948
1948
1948
1949
1949
1952
1952
1953
1959
1963
1963
1964
1964
1967
1967
1968
1969
1969
1969
1969
1971
1971
1972
1972
1972
1973
1973
1975
1975
1975
1975
1975
1976
1976
1978
1978
1980
1983

160
80
160
120
320
240
240
160
120
80
120
80
160
240
60
160
320
160
320
120
120
80
80
160
160
160
240
120
160
640
160
160
160
160
160
240
320
80
80
640

80
<20
80
60
80
80
<20
80
40
40
60
40
80
120
20
80
120
80
160
60
60
40
40
<20
80
80
60
40
40
320
80
80
30
<20
80
80
160
<20
30
120
81

experiment #2
HAI titers
WT
K166Q

experiment #3
HAI titers
WT
K166Q

160
60
160
60
320
240
160
160
80
80
80
80
240
320
80
120
320
160
320
160
120
80
80
120
160
240
240
160
160
640
80
80
80
120
160
160
320
80
60
640

160
80
160
80
320
240
160
160
80
80
80
80
160
240
60
120
320
160
320
160
120
80
80
80
160
240
320
160
160
640
120
120
80
160
160
120
320
80
80
640

80
<20
80
30
80
80
<20
60
30
40
40
40
80
120
30
60
160
80
160
80
60
30
30
<20
80
80
30
30
30
320
30
30
30
<20
60
60
160
<20
20
80

60
<20
80
30
80
80
<20
80
30
40
30
40
60
120
20
60
160
80
160
80
60
30
40
<20
80
80
30
40
40
320
60
40
30
<20
80
60
160
<20
40
80

Table 2: HAI titers using sera from healthy donors from the United States.
Sera were isolated from 195 healthy donors from the state of New York during the 20132014 influenza season. HAI assays were performed using viruses with either wild-type
A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation. For
each serum sample, we completed 3 independent HAI assays. Shown are samples that
had at least a twofold reduction in HAI titer using the mutant virus in 3 independent
experiments.
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Table 3

sample ID

YOB

experiment #1
HAI titers
WT
K166Q

N-33
N-42
N-93
N-72
N-70

1973
1975
1977
1979
1980

160
40
120
30
160

60
<10
30
<10
80

experiment #2
HAI titers
WT
K166Q

experiment #3
HAI titers
WT
K166Q

120
30
60
30
120

80
30
60
20
120

40
<10
30
<10
60

30
<10
20
<10
40

Table 3: HAI titers using sera from healthy donors from Mexico.
Sera were isolated from 45 healthy donors from Mexico during the 2013-2014 influenza
season. HAI assays were performed using viruses with either wild-type
A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation. For
each serum sample, we completed 3 independent HAI assays. Shown are samples that
had at least a 2-fold reduction in HAI titer using the mutant virus in 3 independent
experiments.
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Table 4
K166-specific donors

I.D.

YOB

Chile/83

Texas/91

NC/99

SI/06

CAL/09

CAL/09-K166Q

CAL/09-WT

CAL/09-K166Q

visit 2
(post-vaccine)

USSR/77

visit 1
(pre-vaccine)

1
6
7
13
21

1979
1966
1966
1982
1958

240
160
40
80
60

160
120
60
40
30

320
240
30
80
80

60
120
10
40
40

80
240
60
60
80

120
<10
<10
10
<10

20
<10
<10
<10
<10

160
40
120
160
60

20
10
<10
10
20

other donors

I.D.

YOB

Chile/83

Texas/91

NC/99

SI/06

CAL/09

CAL/09-K166Q

CAL/09-WT

CAL/09-K166Q

visit 2
(post-vaccine)

USSR/77

visit 1
(pre-vaccine)

2
5
8
9
10
15
17
19
20
22
23
24

1976
1949
1961
1977
1983
1961
1956
1961
1945
1956
1975
1968

80
10
40
80
80
<10
40
80
40
30
40
<10

80
<10
<10
80
<10
<10
<10
40
<10
30
<10
<10

120
<10
30
80
320
<10
30
160
<10
60
240
30

<10
10
80
<10
240
<10
80
80
<10
<10
80
<10

<10
40
120
<10
320
<10
120
80
<10
<10
120
<10

60
10
<10
<10
<10
<10
10
<10
<10
<10
<10
<10

60
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10

80
40
80
120
240
80
20
20
240
240
160
60

60
40
80
80
320
80
20
20
320
240
160
60

84

Table 4: Vaccination elicits K166 HA specific responses.
HAI assays were completed using sera isolated from healthy donors before and after
vaccination with the monovalent pH1N1 virus in 2009. Post-vaccination sera were
collected 30 days after vaccination. HAI assays using post-vaccine sera were
completed 3 independent times and assays using pre-vaccine sera were completed 2
independent times.
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Table 5

First
Infection

second
infection

A/USSR/90/77

A/CA/07/09

A/Chile/01/83

A/CA/07/09

A/SI/06/86

A/CA/07/09

A/CA/07/09

A/CA/07/09

None

A/CA/07/09

animal
7982
7983
7984
7985
7991
7993
7994
7995
7987
7988
7989
7990
7996
7997
8000
8001
1487
1488
1481
1504
8002
8009
8010
8012
8013
8014
8015
1486
1497
1492

day 14
WT K166Q
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
400
800
800
1600
1600
1200
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<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
400
800
800
2400
1600
1600

day 84
WT K166Q
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
80
<10
<10
60
<10
<10
<10
<10
200
400
300
ND
ND
ND

<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
120
<10
<10
80
<10
<10
<10
<10
200
400
200
ND
ND
ND

day 98
WT K166Q
800
800
300
800
2400
800
600
400
1200
800
800
1600
1200
240
600
800
6400
3200
2400
4800
1600
1600
4800
1600
160
2400
2400
ND
ND
ND

800
800
300
600
2400
1200
600
600
800
400
400
1600
400
160
800
800
6400
3200
3200
6400
2400
2400
6400
2400
160
2400
1600
ND
ND
ND

Table 5: Sequential infection in ferrets can elicit K166 HA specific Abs.

Ferrets were infected with a sH1N1 virus and bled 14 and 84 days later. Animals were
then infected with a pH1N1 strain and bled 14 days later (98 days post first infection).
Sera were isolated and HAI assays were completed using WT and K166Q HA pH1N1
viruses. Data are representative of three independent HAI assays. The three ferrets with
K166 HA specific Ab responses had >twofold changes in HAI titer using the K166Q virus
in three independent experiments. Red highlights twofold or greater reductions in HAI
titer using K166Q HA pH1N1 virus compared to WT HA pH1N1 virus. ND, not
determined.
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Table 6

A/CA/07/09-WT HA

A/CA/07/09-K166Q HA

YOB
1943
1948
1949
1971
1972
1973
1973
1975
1978
1983
1986
1986
1986
1987
1987
1988
1990
1991
1992
1992

A/CHOP/1/2013

sample
#
40-49
40-44
40-16
70-52
70-36
70-84
70-86
70-23
70-19
80-48
80-10
80-26
80-74
80-30
80-34
80-56
90-01
90-24
90-12
90-13

A/CA/07/09-WT HA

HAI titers

in vitro
neutralization titers

20
160
80
40
120
40
60
80
30
320
160
80
40
20
160
20
40
60
160
80

<10
30
<10
<10
10
<10
20
<10
<10
30
160
80
40
10
160
<10
10
20
60
80

24
453
160
190
381
160
190
226
95
1076
761
113
135
67
381
17
48
34
190
190

12
95
20
28
95
57
67
20
10
80
1810
160
113
113
538
34
80
95
226
320

Table 6: Characterization of K166 HA-specific sera.

We further characterized several serum samples that had immunodominant K166 HA
specific Abs (light grey = K166 HA specific sera from individuals born prior to 1985;
darker grey = sera from individuals born after 1985). HAI assays were completed using
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viruses with the A/California/07/2009 HA-WT and a primary pH1N1 virus isolated from
the Children’s Hospital of Philadelphia (CHOP) in 2013. Additional in vitro neutralization
assays were completed using the reverse-genetics derived viruses. Data are
representative of 2 independent experiments. For each neutralization assay, each
sample was titered 4 times, and geometric mean of these quadruplicate samples is
reported.

89

CHAPTER 4: CONCLUDING REMARKS
AND FUTURE DIRECTIONS
It has long been held that exposure to an antigen leads to an anamnestic
response that can provide protection. Thucydides recorded that in the second year of
the Peloponnesian war (430 BCE) Athens suffered from a terrible plague, and that the
sick found the most help from those who had recovered from the disease as these “had
now no fear for themselves; for the same man was never attacked twice - never at least
fatally. And such persons not only received the congratulations of others, but themselves
also, in the elation of the moment, half entertained the vain hope that they were for the
future safe from any disease whatsoever” (Thucydides, 431 BCE). This observation of
protection has lead to the development of vaccines, most of which are thought to
function by inducing a protective Ab response as well as eliciting memory B cells that are
poised to respond rapidly to a secondary exposure. However, when the antigen used to
recall a previously primed response differs from the original priming antigen as is the
case with rapidly mutating viruses such as influenza virus or HIV, this complicates the
recall response.
Shifting the antibody response
Early influenza studies suggest that recalling previously elicited influenza specific
B cells that have only a low affinity for the new, mutated strain may be detrimental to the
development of a higher affinity de novo response to the more recent strain. However, it
has also been found that while de novo Ab responses specific for the secondary strain
may be lower in individuals who have been pre-exposed to an antigenically different
strain, the viral titers themselves are also lower in these pre-exposed individuals,
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suggesting that additional protection and thereby a lower dose of antigen may be
responsible for the reduction in de novo Ab titers (Kim et al., 2009).
Additional work has also shown that previous exposure can affect the Ab
repertoire by shifting the focus of the Ab response to epitopes that are conserved
between two sequentially infecting strains (Li et al., 2013; Wrammert et al., 2011). This
is thought to be due to MBC clones responding more efficiently and therefore
outcompeting naïve B cell clones that are specific for newly formed epitopes (Hebeis et
al., 2004; Liu et al., 1995; Martin and Goodnow, 2002; Tangye et al., 2003).
Interestingly, we found that the majority of the mAbs that we produced in PR8 preexposed mice were specific for the Sb and Sa sites on the distal head of the influenza
HA in both the mice boosted with the PR8 strain or the antigenically distinct S12a strain.
This suggests that shifting immunodominance hierarchies may require more extensive or
precise alteration of the Ab footprint or additional exposures, as the antigenically drifted
strain could recall previously elicited clones of relatively low affinity. Shifting Ab
immunodominance to highly conserved sites is the target of several experimental
vaccine regimens designed to broaden and increase protection against rapidly mutating
and diverse viral populations (Ellebedy et al., 2014; Krammer et al., 2013; Wei et al.,
2010). Thus we see that our goals have not changed much from the time of the
Peloponnesian war when many hoped their past infection would protect them from a
broader array of disease. Understanding how Ab specificity changes after a secondary
response to an altered antigen will help us better understand not only how these
changes may affect protection, but also inform future vaccine design.
Here we observe how Ab fine specificity changes early in the secondary
response to an antigenically drifted virus with a heavily mutated HA molecule. We found
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that exposure to a drifted strain increased the proportion of Abs that were cross-reactive
between the two strains, but rather than focusing the Ab response on highly conserved
epitopes in the stalk or head region of the HA, vaccination with the antigenically drifted
S12a strain recalled Ab specificities that had slightly altered footprints in the variable
regions of the HA head. This is in contrast to other published studies that elicited Abs to
the highly conserved HA stalk domain (Krammer et al., 2013; Malherbe et al., 2011;
Wang et al., 2010; Wei et al., 2010). However, our study differs from these in that we
sequentially exposed mice with virus that had an intact but mutated HA head domain of
the same HA subtype, and we examine the response after a second exposure. This
suggests that the head domains may need to be more structurally distinct or that more
repetitive vaccination may be required to elicit HA stalk-specific Ab responses. In our
system, many of the Abs recalled at this early stage by S12a vaccination had a high
affinity for the priming PR8 strain, but a low or immeasurable affinity for the S12a strain.
This was in contrast to vaccination with a completely unrelated influenza strain such as
B/Lee/1940, or an influenza strain that expressed an H3 HA (J1, A/HK/1/68 HA) which
failed to recall PR8-specific cells into a secondary response despite eliciting new non
cross-reactive Abs. This suggests that a certain degree of cross-reactivity is required,
the threshold of which is still unknown.
Unexpected protection is elicited by low affinity antibodies
We found that B cell clones with very low to immeasurable affinity to the boosting
strain can be recalled in secondary responses and that these clones may provide early
protection in vivo to the boosting strain. This demonstrates the sensitivity of the BCR in
recognizing antigen, and also the ability of soluble Abs to protect even with low affinity
binding. How these Abs manage to neutralize virus despite their low affinity is yet to be
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elucidated. Studies have shown that in vivo components of the immune system such as
complement and Fc receptors enhance influenza-specific Ab mediated protection,
particularly for Abs that are broadly cross-reactive or fail to neutralize in vitro (Feng et
al., 2002). Several mouse models can be used to determine the role of these
components in enhancing the low affinity Ab mediated protection evidenced in our work.
While we transferred our mAbs into WT BALB/c mice, mice that have particular Fc
receptor genes knocked out (such as FcRγ-/-, FcγRI-/-, FcγRIIb-/-, FcγRIII-/-, FcγRIV-/-,
or FcRn-/- mice) can be used to test the contribution of particular receptors on the
neutralization capability of specific Abs. In addition, recombinant mAbs can be
engineered with Fc region mutations that abrogate or enhance binding of the Fc region
to particular Fc receptors (DiLillo et al., 2014). Complement component C1q can also
affect influenza virus-specific Ab mediated neutralization (Feng et al., 2002). The effect
of C1q on Ab mediated neutralization can be tested by in vitro neutralization assays with
purified C1q protein or using a C1q knockout mouse (Warren et al., 2002).
In addition to providing early protection, the recall of OAS Abs in a secondary
response may have additional benefits. During a primary Ab response, autoreactive B
cell clones are negatively selected while antigen-specific B cell clones are positively
selected (Hande et al., 1998). While OAS clones may still reenter germinal centers and
gain additional somatic mutations that increase their degree of autoreactivity, OAS
clones which have been previously positively selected for their antigen-specificity may
outcompete potentially autoreactive naïve clones. For instance, approximately half of
the Cb-specific clones in the primary response to PR8 virus in BALB/c mice are encoded
by a single Vk gene and one of two closely related VH genes (Kavaler et al., 1990). This
group of B cell clones is excluded from the germinal center and does not form a memory
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response (Kavaler et al., 1991; Rothaeusler and Baumgarth, 2010). Of note, one
mechanism of inducing self tolerance is to exclude autoreactive B cell clones from the B
cell follicle (Cyster et al., 1994; Mandik-Nayak et al., 1997). This particular group of B
cell clones is not evident after secondary exposure, potentially due to it being
outcompeted by recalled MBCs that are poised to respond rapidly to antigen (Kavaler et
al., 1991). Recall of cross-reactive and OAS clones from the MBC repertoire may limit
the activation of potentially autoreactive B cell clones in a similar manner as its exclusion
of this particular set of Cb-specific B cell clones that are excluded from the memory
response for an as yet unknown reason.
The effect of previous exposure on de novo antibody responses
We found that while S12a vaccination was able to boost a PR8-specific Ab
response, this did not come at the cost of S12a-specific Ab titers. While our attention
has been focused on the PR8-specific Abs recalled by S12a vaccination, we also
isolated mAbs that were S12a-specific with immeasurable binding for PR8. These
mAbs, isolated 3 days after S12a exposure, were all IgM isotype Abs. We hypothesize
that these are early primary response Abs arising from previously naïve B cell clones.
Due to the limited number of primary clones that we isolated at this early time point, we
did not fully map the binding footprints of these mAbs. However, future studies should
determine if the primary S12a-specific Ab repertoire is significantly affected by previous
exposure to an antigenically distinct influenza virus. This could be done by expanding
the panel of suspected primary S12a mAbs elicited in PR8 strain pre-exposed mice and
comparing the binding footprints with S12a-specific primary mAbs elicited in previously
naïve mice. Should there be a difference in specificity of Abs from PR8 strain preexposed mice, this could be due to competition for antigen or due to epitope shielding by
94

soluble Abs. Epitope shielding has been predicted to modify the fine specificity of the Ab
response in a number of disease models (Tsouchnikas et al., 2015). To test whether
competition for antigen affects the fine specificity of the response, one would first
determine if there is an antigen dose dependent effect. As an additional control, one
should compare S12a “primary” hybridomas from mice pre-exposed to the J1 strain
which has a very distinct H3 HA and fails to recall PR8-specific clones as S12a can.
Finally, one can analyze the “primary” S12a Ab repertoire in PR8 virus pre-exposed
transgenic mice that fail to secrete soluble Ab to determine the effect of influenza virusspecific soluble Ab on the development of a de novo primary response to an
antigenically drifted strain. These experiments would elucidate the potential effects of
previous influenza virus exposure on the Ab repertoire developed in response to a novel,
antigenically drifted influenza strain.
Maintaining diversity in the memory B cell repertoire
Our studies show that boosting sequentially vaccinating mice with antigenically
drifted strains of influenza shaped a repertoire that included not only highly crossreactive B cell clones, but also B cell clones that appeared to be specific for a single
strain. This raises the question of how a diverse influenza-specific repertoire is
maintained. We know that influenza-specific Abs can last a lifetime in humans, with Abs
specific for the 1918 influenza pandemic strain still measurable in the very elderly
(Krause et al., 2010). In fact, these Abs appear to be protective as evidenced by the
protection of the elderly to the 2009 pH1N1 strain that exhibited some cross-reactivity to
the 1918 pandemic strain (Ikonen, 2010). Despite this, new influenza-specific Abs are
frequently acquired. There has been evidence that there is competition for a plasma cell
niche in the bone marrow that provides survival signals to long-lived plasma cells that
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periodically makes room for new plasma cells while still maintaining memory (Radbruch
et al., 2006). Our studies show that the S12a strain can recall clones not only specific
for itself but also those clones that have a low affinity for S12a and bind predominantly to
a previously encountered strain. Similar evidence has been found in humans where
recent influenza strains are shown to boost the titers of previously circulating strains
(Fonville et al., 2014). This may be an important mechanism to broaden the influenza
repertoire and enhance protection to future strains.
In addition, recent research suggests that the majority of MBCs exit the germinal
center earlier than most long-lived plasma cells (Weisel et al., 2016). This suggests that
although some memory cells are highly somatically mutated and may be recalled to
diverse strains, many MBCs may not be as strain-specific as their highly mutated longlived plasma cell relatives. This could impact the immune repertoire as highly specific
long-lived plasma cells can provide protection in the form of secreted Ab, while the
influenza-specific MBC population may remain less mutated but poised to rapidly mutate
in the necessary direction to create strain-specific immunity.
New epitopes are potentially elicited by sequential exposure
While many mAbs have been mapped to the surface of HA by mutant selection,
the antigenic sites previously described are by no means complete representations of
potential epitopes. As most antigenic site determination has relied on analysis of viral
mutants, residues that are functionally constrained and residues bound by nonneutralizing Abs that don’t positively select for viral mutants are potentially overlooked.
Therefore, the previously described antigenic sites likely represent the binding sites of
the dominant neutralizing Abs, but not necessarily non-neutralizing Abs or Abs that bind
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to highly conserved sites. These neglected groups can have important consequences
for the immune response. Abs that bind to highly conserved sites are of particular
interest as they have the potential to be more broadly cross-reactive and may therefore
protect against a wider range of antigenically drifted strains of influenza.
Non-neutralizing Abs may also play an important role in susceptibility to infection.
Little is known regarding the proportion of non-neutralizing Abs that is elicited in
response to vaccination, infection, or sequential exposure. To determine the footprints
of non-neutralizing antibodies, one could follow one of two approaches. First, one could
introduce mutations throughout the HA, not only in those sites previously isolated after
incubation with neutralizing antibodies, and test reactivity of non-neutralizing Abs to this
expanded panel. This would however exclude those non-neutralizing Abs that bind to
epitopes that are highly conserved due to functional constraints. Second, one could cocrystallize Abs with HA to determine the binding site of non-neutralizing Abs that bind to
a highly conserved site. Such non-neutralizing Abs could be physiologically important as
they could be recalled after sequential exposure without contributing to neutralization.
While the majority of both the PR8 strain-specific and cross-reactive mAbs that
were elicited in our experiments bound to previously defined regions of the HA head, a
number of mAbs bound to all of the viral mutants in our antigenic map panel. As our
viral mutant panel is not exhaustive, these mAbs may bind to previously defined
epitopes that are not addressed by our panel, or these mAbs may require more than one
mutation in their footprint to abrogate binding. However, there is also the possibility that
these mAbs bind outside of the previously dominant antigenic sites. Preliminary results
using recombinant chimeric HA suggest that the unmapped mAbs in our studies are not
HA stalk binding mAbs. A number of approaches can be used to define the presently
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unclear binding footprint of these mAbs. PR8-specific mAbs that fail to bind S12a can
be tested by ELISA against a panel of sequential mutants that contain between 1 and 13
mutations present in S12a to determine which of the mutations in the S12a strain
abrogate binding. This will be particularly informative as it may be necessary for several
mutations to be in place before the mAb fails to bind. Cross-reactive mAbs that bind to
both the PR8 and S12a strains can be incubated with virus to isolate viral mutants that
abrogate mAb binding to determine the possible locations of the binding footprint. This
footprint could then be tested and expanded by additional ELISAs using viruses
engineered to have mutations in those regions. Should these mAbs fail to neutralize
virus in vitro, it will not be possible to isolate viral escape mutants in this manner.
Instead, these mAbs can be tested against a panel of antigenically drifted viral isolates
that have circulated since the PR8 strain was first isolated in 1934 to determine if any
mutations have been randomly acquired throughout time that abrogate binding of these
cross-reactive mAbs.
A potential mechanism for OAS
We have found that even PR8 strain-specific clones that have very low affinity for
the S12a strain are recalled into a secondary Ab response following an S12a
vaccination. Many of these clones have immeasurable affinity by ELISA. However,
previous studies have shown that the sensitivity of the BCR can be much greater than
that of soluble Ab (Lingwood et al., 2012). While the somatically mutated soluble Abs
tested have measurable affinity for antigen, soluble Abs using the germline sequence do
not. The germline Abs tested do however bind to antigen when expressed on the cell
surface as BCR. We hypothesize that S12a virus immunization is able to recall PR8
strain-specific Abs despite their low affinity for the S12a strain because the BCR has an
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increased sensitivity to the S12a virus HA in comparison to soluble Ab. Preliminary
results in our laboratory have shown that plate-bound PR8-specific mAbs elicited in PR8
strain pre-exposed mice boosted with the S12a strain have a higher relative affinity for
S12a virus HA than soluble mAb. This suggests that the conformation of Ab on a
surface can increase the avidity of PR8 strain-specific mAbs for S12a virus. To test this
hypothesis more meticulously in a more physiological setting, PR8 strain-specific mAbs
with immeasurable S12a-specific affinity can be artificially expressed on the cell surface
and binding to soluble antigen can be assessed by fluorescent antigen or by calcium
indicator. This will indicate whether PR8 strain-specific mAbs recalled by S12a virus
vaccination bind to S12a virus when expressed in a membrane bound form. This is of
significance to the field of B cell immunity as it calls into question the sensitivity and
comprehensiveness of analyses that measure the Ab repertoire using soluble Abs.
The effect of previous influenza virus exposure on influenza virus susceptibility
While our studies in a mouse model highlight how the fine specificities of Abs
change after sequential exposure and outlines a potential protective role for OAS Abs,
humans are continuously exposed to antigenically drifted strains of influenza that have
varying degrees of similarity. In 2009, a new pH1N1 strain quickly replaced the
previously circulating sH1N1 strain. The pH1N1 strain has a highly dissimilar head
domain compared to previously circulating sH1N1 strains and has continued to
accumulate mutations over time.
During the 2013-2014 influenza season, middle-aged adults were found to have
an increased influenza disease burden. Studies have shown that different age groups
have different influenza-specific Ab repertoires. We hypothesize that the age-specific
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increase in susceptibility in the 2013-2014 influenza season is due to a recently acquired
mutation that abrogates Abs prevalent in middle-aged adults due to their unique preexposure history. We find that human serum samples from middle-aged adults are more
likely to exhibit reduced binding and neutralization against a mutant virus that contains
the recently acquired K166Q HA mutation. mAbs that fail to bind to K166Q HA mutant
influenza virus also fail to protect mice against infection with a K166Q HA mutant virus in
an in vivo passive transfer experiment. These results suggest that an Ab repertoire
focused on this newly mutated region negatively affects protection against infection.
We hypothesize that the K166 HA-specific Abs affected by the recent K166Q HA
mutation are expressed by B cells that are the progeny of B cells previously elicited by
sH1N1 strains. This is supported by analysis of human serum samples collected before
and after immunization with the 2009 pH1N1 strain. This analysis shows that
vaccination of middle-aged adults with the 2009 pH1N1 strain elicits an Ab response in
some individuals that has reduced binding to a pH1N1 strain engineered to have a
K166Q HA mutation. In addition, pH1N1 infected ferrets previously infected with a
sH1N1 strain that circulated in the early 1980s (when middle-aged individuals were
young) are more likely to have an Ab response that exhibits reduced binding to the new
K166Q HA mutant strain. Taken together, these results suggest that while previous
exposure shifts the Ab response to epitopes conserved between sequentially circulating
viral strains, the shift in epitope immunodominance can affect susceptibility should a
previously conserved region acquire a mutation by continued antigenic drift.
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Updating the antibody repertoire
Our work suggests that a new mutation has been acquired by circulating pH1N1
strains that abrogates binding of Abs commonly prevalent in middle-aged adults. We
therefore recommend that the H1N1 component of the influenza vaccine be updated to
include a currently circulating strain that has a K166Q HA mutation. However, we do not
know whether individuals vaccinated or infected with a Q166 HA viral strain will produce
protective Abs to this epitope, or whether the antibody response will be shifted to a
different region of the HA. To test whether an updated strain would elicit Q166-specific
Abs in these individuals, serum samples collected before and after vaccination or natural
infection with a Q166 HA viral strain should be analyzed by HAI assay and by in vitro
neutralization assay. This will illustrate how efficiently exposure to a highly similar
influenza strain with a relevant antigenic mutation can update an Ab repertoire that is
focused on a recently mutated site.
Understanding B cell immunodominance
We propose that the H1N1 component of the influenza vaccine be updated
despite the fact that more conventional surveillance techniques that use primary ferret
sera fail to determine that the K166Q HA mutation is antigenically relevant. We suggest
that this is due to the fact that the primary Ab response in previously naïve ferrets
infected with the pH1N1 strain is focused on a region of the HA encompassing HA
residues 156, 157, and 158 that is not affected by a mutation at residue 166 (Li et al.,
2013). Why epitopes containing residues 156-158 of the HA are immunodominant for
the ferret Ab response to the pH1N1 strain is currently unknown. In fact, the mechanism
of B cell immunodominance is largely unexplained. Unraveling this mystery would be of
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great value to future vaccine design and the understanding of the B cell response to
infection, autoimmunity, and tumor antigens.
Immunodominance is not permanent and can be shifted from one epitope to
another. In fact, shifting humoral immunodominance to subdominant but broadly
neutralizing epitopes is the strategy of a number of experimental universal influenza
vaccines. However, although it has been possible to shift the immune response to
conserved epitopes like the HA stalk, this has been a transient effect as re-infection or
immunization of an individual tends to shift the Ab response back to the dominant HA
head domain epitopes (Andrews et al., 2015; Ellebedy et al., 2014). It has been
suggested that subdominant epitopes only become dominant when they are recalled in
the absence of competition from previously elicited clones to typically dominant epitopes.
This would explain why previously subdominant HA stalk-specific B cell clones become
more prevalent in humans who are infected or immunized with the 2009 pH1N1 strain
which has an extensively mutated HA head domain in comparison to previously
circulating sH1N1 strains (Wrammert et al., 2011). This is also hypothesized to be the
reason why sequentially immunizing mice with HA that have conserved HA stalk
domains but highly diverse head domains shifts the Ab response towards the stalk
domain (Ellebedy et al., 2014; Krammer et al., 2013). However, while previously elicited
B cell clones specific for subdominant epitopes may be temporarily dominant, the
repertoire remains diverse. Once exposed to an HA head domain, new B cell clones
specific for those dominant epitopes arise and these can once again outcompete B cell
clones that are specific for subdominant epitopes. This would explain why the HA stalkspecific response in individuals who are infected or immunized with the 2009 pH1N1
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strain lose immunodominance against the HA stalk domain after a second exposure to
the pH1N1 strain (Andrews et al., 2015).
If one could limit the repertoire to broadly cross-reactive clones, those clones that
are specific for the dominant but more strain-specific epitopes would not outcompete the
subdominant broadly cross-reactive clones. However, to make this a possibility, one
would not only need to create a vaccine that lacks the previously dominant epitopes, but
it would also have to be so strongly neutralizing that any natural exposure to circulating
influenza strains would fail to mount a de novo Ab response to the dominant but variable
head domain as any Ab response to more dominant epitopes would eventually
outcompete the more broadly neutralizing subdominant clones. This has been
attempted in the form of “headless” HA vaccines (Steel et al., 2010; Uranowska, 2014;
Yassine et al., 2015). The HA protein is initially expressed as an HA0 protein which is
later cleaved into the HA1 and HA2 subunits. These two subunits are bound together by
disulfide bounds. The HA head domain is encoded entirely by the HA1 region, while the
HA stalk domain is encoded by both the HA1 and HA2 subunits. Should these subunits
separate, the head domain remains intact while the stalk domain is incomplete. HA1
subunits have been shown to induce an Ab response, whereas the HA2 subunit has not
(Khurana et al., 2011b; Sguazza et al., 2013). This could potentially affect
immunodominance of the head domain and reduced immunogenicity of the stalk domain
should the disulfide bonds be cleaved in vivo (Hogg, 2003). The headless HA constructs
that have been artificially created contain the HA2 subunit and the region of HA1 that
contributes to the HA stalk domain while excluding the region that encodes the HA head
domain. Interestingly, sera collected from mice immunized with “headless” HA failed to
neutralize virus in in vitro neutralization assays, but these mice were protected against in
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vivo challenge with a homologous virus (Steel et al., 2010). This contrast might be
explained in light of recent results that demonstrate that many stalk-specific Abs require
Fc receptor binding for neutralization activity (DiLillo et al., 2014). However, while these
headless HA constructs initially elicited an Ab response that was more broadly crossreactive in a subset of vaccinated mice, whether this remained true after viral challenge
remains unaddressed. Based on our current experience with pH1N1 infections, this
appears to be unlikely, underscoring the need to more fully understand the mechanisms
of B cell immunodominance.
Concluding Thoughts
The observation of OAS has been paradoxical to the theory of clonal selection as
an antigenically drifted strain of influenza virus recalls B cell clones specific for a
previously circulating strain that appear to fail to bind to the new, drifted strain.
However, we know that a certain degree of cross-reactivity is required. While we might
expect antigen to induce the recall of the strongest affinity B cell clones, antigenically
drifted strains of influenza can recall B cell clones that have extremely low affinity for the
new drifted strain relative to the affinity to an older strain. While this can occur at the
expense of mounting a de novo Ab response to the drifted strain in the case of
sequential infection, in our experiments there is no detrimental effect on overall titers to
the drifted strain after sequential vaccination with inactivated virus. In addition, the OAS
Abs elicited after recall by a drifted strain can have a positive effect on protection and
this can be further affected by somatic hypermutation. However, while we show that
OAS Abs can contribute to a protective immune response, shifting the Ab response
towards regions conserved between the previously experienced strains can potentially
affect individual susceptibility to infection to further drifted strains. We show that an HA
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mutation, K166Q, negatively affects binding of human sera of middle-aged adults and
that a K166 HA-specific mAb isolated from a middle-aged adult fails to neutralize K166Q
HA mutant viruses. This therefore highlights the pros and cons of shifting the Ab
repertoire in response to sequential exposure to antigenically drifted strains of influenza
virus (Figure 21). The challenge of future endeavors in this field will be to determine
how to manipulate these repertoire changes to elicit the Abs of choice against not only
influenza virus, but also other difficult targets, such as HIV and tumor antigens. Our
ability to design more effective vaccines and antibody therapies will continue to improve
as we put together piece by piece the puzzle that is Ab immunodominance and the evershifting Ab repertoire.

105

Figure 21
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Figure 21. A schematic diagram of the effect of sequential exposure to
antigenically drifted strains of influenza on the specificity and function of the Ab
repertoire
(A) A primary HA-specific B cell response to a particular ‘blue’ strain elicits Abs that are
predominantly strain-specific (represented by a light shade) and not highly cross-reactive
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(represented by a darker shade). (B) After a secondary response to the same ‘blue’
strain, Ab specificity may shift to other epitopes, but the B cell clones remain
predominantly strain-specific, with only a slight increase in the degree of cross-reactivity
to antigenically drifted strains. (C) In contrast, the fine specificity of B cell clones elicited
by heterologous exposure differs from those elicited by a homologous recall response.
Individuals who are pre-exposed to the ‘blue’ strain and then boosted with an
antigenically distinct ‘green’ strain elicit not only a de novo Ab response against the
‘green’ strain, but also recall Abs previously elicited by the ‘blue’ strain that have varying
degrees of cross-reactivity. There is an increased proportion of B cell clones expressing
highly cross-reactive Abs, but also recall of B cell clones expressing Abs with a higher
affinity for the ‘blue’ strain than the ‘green’ strain. Many of these Abs with a higher
affinity to the priming ‘blue’ strain are protective against the ‘green’ strain. However, the
shift in Ab fine specificity after sequential exposure not only affects cross-reactivity and
protection against the ‘green’ strain, but may affect susceptibility to a novel antigenically
drifted strain that has a mutation that abrogates binding of these Abs.
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